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After being described in the 1970s as cytotoxic cells that do not require MHC-dependent
pre-activation, natural killer (NK) cells remained the sole member of innate lymphocytes
for decades until lymphoid tissue-inducer cells in the 1990s and helper-like innate
lymphoid lineages from 2008 onward completed the picture of innate lymphoid cell
(ILC) diversity. Since some of the ILC members, such as ILC1s and CCR6− ILC3s,
share specific markers previously used to identify NK cells, these findings provoked the
question of how to delineate the development of NK cell and helper-like ILCs and how to
properly identify and genetically interfere with NK cells. The description of eomesodermin
(EOMES) as a lineage-specifying transcription factor of NK cells provided a candidate
that may serve as a selective marker for the genetic targeting and identification of
NK cells. Unlike helper-like ILCs, NK cell activation is, to a large degree, regulated
by the engagement of activating and inhibitory surface receptors. NK cell research
has revealed some elegant mechanisms of immunosurveillance, coined “missing-self”
and “induced-self” recognition, thus complementing “non-self recognition”, which is
predominantly utilized by adaptive lymphocytes and myeloid cells. Notably, the balance
of activating and inhibitory signals perceived by surface receptors can be therapeutically
harnessed for anti-tumor immunity mediated by NK cells. This review aims to summarize
the similarities and the differences in development, function, localization, and phenotype
of NK cells and helper-like ILCs, with the purpose to highlight the unique feature of NK
cell development and regulation.
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INTRODUCTION
In the mid-70s of the last century, two groups independently reported the presence of
small lymphocytes with non-MHC-restricted cytolytic activity against cells expressing tumor
antigens in mice (1–4). Such “natural” killer (NK) cells, capable of cell-mediated, rapid
cytotoxicity in a germline-encoded receptor-dependent fashion upon encountering of target
cells, were observed in humans as well (5). NK cells remained the only subset of innate
lymphocytes for two decades until an additional subset was discovered, which expressed
the integrin α4β7, lymphotoxin (LT)α1β2, and lymphoid cytokine receptors. However, this
newly described cell subset was giving rise to neither T-lymphocytes nor B-lymphocytes.
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They were named lymphoid tissue-inducer (LTi) cells because
they were among the first cells to infiltrate lymph node anlagen
during embryogenesis and hence are instrumental for the
development of most secondary lymphoid tissues (6).
Furthermore, from 2008 onwards, several groups reported the
discovery of new types of non-T and non-B lymphocytes which,
like NK cells and LTi cells, require the transcriptional regulator
inhibitor of DNA-binding 2 (ID2) and the common gamma chain
(γc) of the cytokine interleukins (IL)-2, 4, 7, 9, 15, and 21 for
their development and/or maintenance (7–21). These cells were
termed “innate lymphoid cells” (ILCs), which constitute lineages
of professional cytokine-producing cells that mirror T helper
cells in the utilization of transcription factors (TFs) required to
establish distinct patterns of lineage-specific cytokine production
and effector functions. It became obvious that the different
ILC populations resemble the functional diversity found in T
helper cell subsets, thus establishing a complementary innate
counterpart to T helper cells (22).
In connection with these findings of ILC diversity, a novel
ILC nomenclature was proposed in 2013 and amended in
2018 (22, 23). In analogy to T cells, two principal subsets of
ILCs can be distinguished: cytotoxic ILCs (i.e. conventional NK
cells) and helper-like ILCs (i.e. ILC1, ILC2, and ILC3) (24,
25). The general division of NK cells and helper-like ILCs is
supported by various findings. First, while there is a common
progenitor to all innate lymphocytes, variably referred to as
early innate lymphoid progenitor (EILP) (26) or innate lymphoid
cell progenitor (ILCP) (27), a more restricted common helper-
like innate lymphoid cell progenitor (CHILP) with reduced
potential for helper-like ILC can only be found downstream
of the bifurcation with the NK cell lineage. Second, all helper-
like ILCs but not NK cells require GATA binding protein
3 (GATA-3) for their differentiation (28). Third, helper-like
ILCs are remarkably tissue-resident cells, whereas NK cells
are circulating cells (29–31). Finally, the use of inhibitory
and activating receptors of the KIR and the Ly49 families
was found in NK cells but not in ILCs. Thus, two principal
lineages of innate lymphocytes exist: helper-like ILCs and
cytotoxic ILCs.
In analogy to T cells, ILCs are divided into functional
groups, based on TFs required for their development as
well as their role in immune responses (22). NK cells
are functionally important for immunity against tumors and
intracellular pathogens via classical perforin-dependent, cell-
mediated cytotoxicity and production of interferon-gamma
(IFN-γ). ILC1s are an important source of IFN-γ and tumor
necrosis factor (TNF) to trigger type 1 immune responses and
limit intracellular infections. While NK cells and ILC1s are
functionally both promoting type 1 immune responses, they
are developmentally dependent on two evolutionary related
T-box TFs: eomesodermin (EOMES) and T-box expressed
in T cells (T-bet) (32). NK cells express both EOMES and
T-bet, but their development is only strictly dependent on
EOMES. NK cells develop in T-bet-deficient mice and have
a relatively mild functional defect (16, 33, 34). In contrast,
ILC1s express T-bet but not EOMES and do not develop in
T-bet-deficient mice (21, 35, 36). ILC2s require GATA-3 and
B-cell lymphoma/leukemia 11B (BCL11B) for development and
produce type 2 cytokines, mostly IL-5, IL-9, and IL-13, as well
as other effector molecules, such as amphiregulin, promoting
worm expulsion and tissue remodeling (12–14, 17, 37–42). Group
3 ILCs include fetal LTi cells and can be further divided into
two groups in adult mice based on CCR6 expression with
different developmental requirements and effector mechanisms
(43, 44). Both CCR6+ ILC3s and CCR6− ILC3s are dependent
on the TF RORγt and produce IL-22 to fortify the epithelial
barrier against infections, damage, and genotoxic stress (45–
51). CCR6+ ILC3s also produce IL-17 and protect from fungal
infections, whereas CCR6− ILC3s down-regulate RORγt and IL-
22, up-regulate the TF T-bet. CCR6− ILC3s in addition acquire
the capacity to produce IFN-γ and transform into ILC1-like
cells (19, 44, 52–55).
Helper-like ILCs were reported as tissue-resident cells
enriched at barrier surfaces and underrepresented in secondary
lymphoid organs (29–31). In contrast, NK cells are patrolling
lymphocytes, which express CD62L to migrate from blood to
lymph nodes (21, 30, 56). As patrolling cells, immune recognition
by NK cells is mediated by the interaction of immunoreceptors
that scan target cells for the expression of their ligands. Therefore,
the development and regulation of NK cells depend on the
interaction of the immunoreceptors and their ligands. Although
the expression of some immunoreceptors (e.g. KLRG1, PD-1) has
been reported for helper-like ILCs as well, their activity seems to
be predominantly regulated by soluble factors such as cytokines
and neuronal factors (21, 35, 52, 57–59).
IMMUNE RECOGNITION STRATEGIES OF
NK CELLS
The complexity of multicellular organisms demands essential
immune recognition strategies to maintain their self-integrity
in a hostile environment. Almost all organisms, from bacteria
to higher animals, possess recognition systems that allow them
to discriminate between self and non-self and possess effector
mechanisms to defend themselves from an invasion of pathogens.
The immune system of vertebrates consists of two arms: innate
and adaptive. Recognition of non-self molecules is broadly
used by both the innate and the adaptive immune system to
protect the host from infections (60). However, although NK
cells are capable of directly sensing non-self molecules, their
development and activation are regulated to a large extent by the
recognition of self molecules. Discrimination between self and
non-self is mediated by an array of stimulatory and inhibitory
immunoreceptors expressed by NK cells. They either recognize
non-self structures directly (Ly49H, NKG2C/CD94) or indirectly
via binding immune complexes to Fc receptors. Alternatively,
they interact with self MHC I (Ly49s and KIR, “missing-self ”
recognition) or with ligands absent on healthy cells (NKG2D and
NKp30, “induced-self ” recognition). The regulation of NK cells,
which relies on cell surface immunoreceptor–ligand interactions,
is complemented by cytokines, such as type I interferons, IL-12,
IL-15, and IL-18 (61–64).
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Non-self Recognition
The recognition strategy of “microbial non-self ” is approached
differently from the innate and the adaptive immune system.
The cellular components of the innate immune system express
germline-encoded receptors, called pattern recognition receptors
(PRRs), which come in two forms: transmembrane receptors and
secreted receptors (60, 65). These molecules recognize conserved
pathogen-associated molecular patterns (PAMPs) or microbe-
associated molecular patterns (MAMPs). The secreted PRRs lead
to the opsonization of microbes and label them for destruction
either by the complement system or by phagocytosis. PRRs
expressed on the cell surface of innate immune cells, such as Toll-
like receptors (TLRs), lead to the activation of immune signaling
pathways, which trigger inflammatory or antimicrobial effector
responses (66, 67).
Upon recognition of PAMPs and MAMPs on microbes by
antigen-presenting cells (APCs), phagocytosis and processing
of antigens in the lysosomal compartment of these cells are
triggered. T cells express strictly antigen-specific T cell receptors
(TCRs) that are generated by somatic genetic recombination,
thereby providing a vast repertoire of specificities. TCRs
recognize self and non-self peptides presented on APCs via
MHC molecules, providing “signal 1” for T cell activation.
However, TCR ligation by itself is not sufficient for efficient T
cell activation. It requires a co-stimulatory signal (“signal 2”),
e.g. provided by APC-expressed CD80 (B7-1) and CD86 (B7-2),
ligands for the constitutively expressed CD28 receptor on T cells
(68). CD80 and CD86 are not expressed by unstimulated APCs
but are rapidly up-regulated following the encounter of MAMPs
or PAMPs, providing an additional “quality control” for T cell
responses. In addition, stimulated APCs produce cytokines and
IFNs, which further enhance T cell responses (“signal 3”). In the
case of naive CD4+ T lymphocytes, distinct cytokines have been
shown to drive the differentiation into one of three T helper (Th)
subsets. IFN-γ and IL-12 are important for inducing Th1 cells,
IL-4 for Th2 commitment, and TGF-β and IL-6 for Th17 cell
differentiation (69–72).
TLR expression was also described on NK cells, but its
contribution to NK cell activation remains unclear. While the
direct activation of NK cells by TLR engagement has been
reported for human NK cells (73), genetic data from mice
demonstrated that TLR signaling to activate NK cells was cell-
extrinsic via mononuclear phagocytes (62). While recognition
of “non-self ” via PRRs may not be central for NK cells, they
express other families of receptors to directly recognize “non-
self ” molecules such as Ly49H in mice or NKG2C/CD94 in
humans (74–76). Ly49H is a stimulatory receptor that recognizes
the MHC-like protein m157 encoded by murine cytomegalovirus
(MCMV), which is expressed in infected cells and confers host
protection in C57BL/6 (B6) mice. It should be noted though
that, in most inbred mouse strains other than B6, m157 binds
to an inhibitory Ly49 receptor, leading to immune evasion.
NK cells can also recognize non-self peptides in the context
of non-classical MHC I molecules, very similar to the immune
recognition strategy of T cells. For example, subsets of NK
cells expressing the stimulatory receptor NKG2C/CD94 were
shown to recognize the UL40 antigen of human cytomegalovirus
presented in the context of the non-classical MHC-I molecule
HLA-E, and this recognition activates NK cells (77). The different
recognition strategies of immune cells are depicted in Figure 1.
Missing-Self Recognition
In 1981, Klas Kärre formulated the missing-self hypothesis (78).
Missing-self recognition was conceived as the capacity of NK
cells to attack cells that fail to express sufficient levels of class I
MHCmolecules. This concept was discovered while investigating
the role of class I MHC molecules in NK cell and T cell
responses to tumor cells (79, 80). Given the role that the class
I MHC antigen presentation pathway plays in the revelation of
virally infected cells to CD8+ T cells, it is not surprising that
many viruses have evolved mechanisms that interfere with this
pathway, thereby binding CD8+ T cells to virus-infected cells
(81). The missing-self hypothesis predicted that NK cells express
inhibitory class I MHC-specific receptors and that the down-
regulation of MHC-I expression on virus-infected cells or tumors
would unleash NK cells from inhibition. Years after postulating
“missing-self recognition,” various classes of inhibitory MHC
class I-specific NK cell receptors were identified. Ly49 receptors
in mice (82) and the structurally unrelated but functionally
analogous KIR family of inhibitory receptors in humans (83,
84) directly interact with class I MHC molecules. Both human
and mouse NK cells express the heterodimeric CD94/NKG2A
receptor, which monitors class I MHC molecules by another
mechanism. CD94/NKG2A recognizes a non-classical MHC
class I molecule, HLA-E in humans and Qa-1b in mice, when
loaded with peptides that are derived from the signal peptide
of classical class I MHC proteins (85). The inhibitory receptors
have an immune-receptor tyrosine-based inhibitory motif
(ITIM) in their cytoplasmic domain. Upon ligand recognition,
phosphorylation of the ITIM’s tyrosine residue serves as a
signal for recruitment of protein tyrosine phosphatases, SHP-
1 and SHP-2, which inhibit cytotoxic activity by further
dephosphorylating tyrosine residues that are critical for NK cell
activation (86, 87).
Missing-self recognition does not require viral infection or
a malignant transformation of target cells. Uninfected and
untransformed cells can be lysed by NK cells, as demonstrated
in NK cell-mediated rejection of F1 bone marrow grafts (88)
and bone marrow of β2-microglobulin-deficient mice that do
not express class I MHC on the cell surface (89). Since T cells
are not capable of recognizing and killing cells that down-
regulated class I MHC expression due to viral proteins that hijack
their expression pathway, NK cells are able to compensate this
immunological function via missing-self recognition of MHC-
deficient target cells.
Induced-Self Recognition
Induced-self ligands of NK cell receptors are molecules that are
absent or only at a very low level expressed on normal cells
but up-regulated on infected cells, stressed cells, or tumor cells
as a marker of “abnormal self.” Induced-self ligands bind to
stimulatory immunoreceptors on NK cells and mediate their
activation, leading to the lysis of the target cell (63, 90). The
activating NK cell receptor natural killer group 2D family
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FIGURE 1 | Principles of immune recognition. The immune system constantly senses the presence or absence of “self” and “non-self” molecules by stimulatory and
inhibitory receptors. Activation of immune cells is triggered by the direct recognition of microbial “non-self,” “missing-self” recognition, or “induced-self” recognition
(illustrations were created with BioRender.com).
(NKG2D) has served as a paradigm for understanding the
recognition of induced-self antigens. NKG2D binds to several
induced-self ligands. The mouse ligands include RAE1α, RAE1β,
RAE1γ, RAE1δ, RAE1ε, H60 (H60a, H60b, and H60c), and
MULT1 (91–96). These NKG2D ligands belong to a group
of non-classical MHC I molecules and contain α1 and α2
extracellular domains with homology to class I MHC molecules.
In humans, MHC class I polypeptide-related sequence A (MICA)
and B (MICB) represent additional NKG2D ligands that are not
present in mice (91). MICA/B possess an α3 domain homologous
to class I MHC molecules, but they neither require β2-
microglobulin for expression nor do they present peptides (90).
Another example of “induced-self recognition” is the natural
cytotoxicity receptor NKp30 which interacts with the B7-like self-
ligand B7-H6, the expression of which is induced on transformed
cells (97). Thus, immunosurveillance of induced-self ligands
by immunoreceptors such as NKG2D and NKp30 allows the
immune system to detect and eliminate cells that have undergone
“stress.” These receptor–ligand pairs represent interesting targets
of anti-tumor therapies. In Tables 1A and 1B, ligand–receptor
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TABLE 1 | (A) Summary of ligand-receptor interactions and their effect on immune cell activation. (B) Summary of self and non-self effects on immune cells when they are
present or absent. Illustrations created with BioRender.com.
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interactions, as well as the functional consequences for NK cell
activation are summarized.
Notably, NK cell-mediated immune regulation is tightly
linked to both classical and non-classical class I MHC molecules.
NK cells sense the absence of classical MHC-I (“missing-self ”)
but also recognize non-classical MHC-I molecules as non-
self or induced-self ligands. In addition, NK cells require the
recognition of self-MHC ligands not only for their activation
but also for proper development, which will be discussed in the
following chapters.
TRANSCRIPTIONAL REGULATION OF
PROGENITOR COMMITMENT TO ALL
INNATE LYMPHOID CELL LINEAGES
The initial steps of ILC differentiation from precursor cells take
place in the fetal liver and after birth in the adult bone marrow
(BM). In Figure 2, ILC progenitors and their differentiation
stages into ILC subsets are presented.
Hematopoietic stem cells (HSCs) give rise to all blood
cell progenitors, among which common lymphoid progenitors
(CLPs) are precursors of all lymphocytes, belonging to both
adaptive and the innate arms of the immune system. It
is generally believed that the CLP differentiates into the
various lymphocyte subsets by integrating environmental signals
that establish characteristic transcriptional programs, usually
regulated via several key TFs, that lead to a step-wise restriction
of their precursor potential and to the instruction of lymphocyte
subset-specific transcriptional circuitry (99–101).
An important conceptual advance of the last 5 years was
the description of multipotent ILC progenitor cells such as α-
lymphoid progenitor (α4β
+
7 αLP), EILP, CHILP, and ILCP, which
have the developmental potential for ILC lineages but can no
longer differentiate into adaptive lymphocytes or myeloid cells
(21, 26, 27, 98). Early evidence indicated that ILC progenitors
may be contained within a population with phenotypical
characteristics similar to CLPs. Indeed Lin− IL-7Rα+ CXCR6−
cells, which in contrast to CLPs expressed integrin α4β7 but were
negative for FLT3, a receptor tyrosine kinase expressed by the
CLPs (102), gave rise to all three groups of ILCs and T cells but
had lost B cell potential (103). The subsequent acquisition of the
chemokine receptor CXCR6 is indicative of the loss of T cell




are referred to as αLPs (103, 104). It became clear, however, that
αLPs are a quite heterogeneous population of innate lymphocyte
progenitors, which was further explored in subsequent work.
The earliest defined subset of ILC-committed progenitors
downstream of the CLP (and contained within the αLP
population) was characterized by high expression of the
transcriptional regulator T cell factor 1 (TCF-1, encoded by
the Tcf7 gene). Such TCF-1high progenitors are referred to as
EILPs or ILCPs. EILPs already show a substantial expression
of nuclear factor interleukin 3-regulated (NFIL3, also known
as E4BP4) and thymocyte selection-associated high mobility
group box protein (TOX) known to be involved in early ILC
differentiation (see below) (26). While the CLP does not express
ID2, a transcriptional regulator required for the differentiation
of all ILCs (105), EILPs express intermediate level of ID2. The
EILP gives rise to all ILC lineages (including NK cells) but lacks
T and B lymphocyte or myeloid potential (26). Unlike other
ILC progenitors and CLPs, EILPs were IL-7Rα low-expressing
cells and developed independently of IL-7Rα signaling. Therefore
this finding provoked the question on whether EILPs might
constitute an alternative route to ILC development because the
upstream and downstream cells are both IL-7Rα+. However,
it was demonstrated in consecutive work that EILPs developed
from CLP transiently down-regulating IL-7Rα expression and
then differentiated into ILC progenitors with increased IL-7Rα
expression (26, 106).
The existence of a common progenitor for ILCs was already
hypothesized years before their discovery, mainly based on the
phenotype of mice deficient for ID2 (107). ID2 belongs to the
family of helix–loop–helix proteins, which form heterodimers
with E-proteins, thus preventing their binding to DNA and
antagonizing the gene regulatory function of E-proteins during
cell development (108). Since Id2−/− mice lacked all ILCs, it
was hypothesized that this phenotype might be explained by
the existence of a common ILC progenitor, which expresses
ID2 and is developmentally dependent on it (12, 105, 109).
Indeed the analysis of ID2 reporter mice [Id2Gfp/+ mice; (110)]
revealed that both mature and immature ILCs expressed ID2
(17, 111, 112). An interrogation of the αLP population for
ID2 expression revealed a population of ID2high cells within
Lin− IL-7Rα+ CD25− integrin α4β
+
7 FLT3
− αLP (21). Upon
transfer and on a clonal level, this cellular subset gave rise to
all three groups of ILCs, including CCR6+ ILC3, but not to
conventional NK cells and was accordingly named CHILP.While
the CHILP did not express any ILC lineage-defining TFs, they
expressed intermediate levels of GATA-3 (17). However, CHILPs
were heterogeneous for the expression of the TF promyelocytic
leukemia zinc finger protein (PLZF) (21). Interestingly, while
PLZF+ CHILP could generate ILC1, ILC2, and CCR6− ILC3,
they lacked the potential to differentiate into CCR6+ (LTi-like)
ILC3s and NK cells (98). These findings might be explained by
data showing that the CHILP contained subsets of CXCR5+ cells,
which gave rise to CCR6+ ILC3s/LTi cells and were not contained
in the PLZF+ population (113, 114). Single-cell sequencing of
ILC progenitors has confirmed the developmental stages of early
ILC commitment and further contributed additional markers,
such as programmed cell death protein 1 (PD-1), to define
PLZF+ precursors (115). Therefore, we will refer to these two
populations of ILC precursors as CHILP-A (ID2+ PLZF− PD-
1−) and CHILP-B (ID2+ PLZF+ PD-1+). Using reporter mice for
several TFs, later studies showed some degree of heterogeneity in
CHILP-A and CHILP-B which could be further subdivided into
cell subsets that were committed to one ILC subset and bona fide
CHILP subsets that still maintained multi-ILC lineage potential
(111–113).
A recent report attempted to challenge the view that ID2high
CHILPs are progenitors to all helper-like ILCs but not to
conventional NK cells (112). This study was based on the
generation of a very bright reporter allele for ID2. Somewhat
expectedly (26), the authors found that ID2int precursors (i.e.
EILP), which could be discriminated in these new reporter
mice, still have NK cell differentiation potential. These results
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FIGURE 2 | Progenitor commitment to innate lymphoid cells (ILCs). Schematic representation of progenitor populations with various differentiation potentials toward
ILCs. The common lymphoid progenitor (CLP) gives rise to B-cells, T cells, and ILCs. The early innate lymphoid progenitors (26) possess the potential for NK cells,
ILC1s, ILC2s, and ILC3s, whereas CHILP-A (21) and CHILP-B (98) possess the potential for ILC1s, ILC2s, and ILC3s as indicated. In square brackets are the
population-defining markers reported in the literature. The transcription factors required for the indicated lineage or transition from one population to another are
indicated within the cells or on the arrows, respectively (illustrations created with BioRender.com).
are supporting previous work which show that EILP expressed
intermediate levels of ID2 and can generate all ILC subsets and
NK cells (26, 106, 116). It is worth noting that during cellular
differentiation processes, TFs often act as gradients rather than
as binary switches. Once past the NK cell bifurcation (Figure 2),
ID2 expression increases (26, 100, 112) and ID2high CHILPs
have a more restricted potential. Collectively, the available
data support a model of ILC differentiation downstream of
CLP with three major bifurcations and consecutively restricted
differentiation potential, namely, TCF1+ ID2int EILP (or
ILCP), ID2high PLZF− CHILP-A, and ID2high PLZF+ CHILP-B
(Figure 2).
Single-cell sequencing data and analysis of multi-color
reporter mice have demonstrated that a further subdivision
of ILC progenitors is technically possible. These findings can
advance the ILC field by defining different ILC progenitors that
have a more restricted differentiation potential and therefore
open the perspective of finding the cues that control the
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commitment and the differentiation of CHILPs into different
ILC cell subsets. However, defining progenitors by clustering
based on highly expressed genes that are detected using single-
cell sequencing comes with the caveat that cell clustering
is not necessarily of biological relevance and differences in
differentiation potential remain to be demonstrated.
Several additional TFs were recognized, which play an
essential role in early commitment to the ILC fate. In addition to
ID2 and PLZF, these TFs include NFIL3, TOX, and GATA-3. The
phenotype of the knockout mice for these TFs was characterized
by a deficiency or a reduction in all or almost all ILC lineages,
except NK and LTi-like cells in GATA-3-deficient mice. NFIL3 is
important for the transition fromCLPs to ILC progenitors, where
the relative expression of this TF increased and its deletion led
to a substantial decrease in ILC progenitor numbers (104, 117–
122). Since the down-regulation of the transcriptional regulator
TOX was described in Nfil3−/− mice in comparison to wild-
type controls, it was proposed that NFIL3 is directly regulating
the expression of TOX, which then acts downstream in ILC
development (104). Indeed Tox−/− mice had a similar phenotype
as that of Nfil3−/− mice and lacked mature ILCs and ILC
progenitors (123, 124). Based on these data, it was proposed
that NFIL3 and TOX orchestrate the transition from CLP to
EILP (106), whereas GATA-3 (28, 125) is required later in ILC
development for the transition to PLZF+ ILCPs. It should be
noted though that NK cells and CCR6+ ILC3s still develop in
GATA-3-deficient mice. Altogether these data indicate that the
developmental potential for NK cell and CCR6+ ILC3s/LTi cell
is consecutively lost during the transition from EILP to CHILP-B
(28, 98, 114, 125, 126).
While ILC progenitors are certainly present in the primary
organs of hematopoiesis, the BM and fetal liver (21, 26, 98),
it should be considered that ILCs may be derived from local
precursors as tissue-resident cells. In mice, fetal ILC precursors
migrated to the intestine before Peyer’s patch organogenesis
and accumulated at the sites where intestinal lymphoid tissue
organogenesis is initiated and became a localized source of
ILC populations (127). While intestinal ILC precursors were
identified based on arginase expression, adult BM ILC precursors
lacked arginase expression, indicating tissue adaption of the ILC
precursor population (127). Since fate-labeling studies suggest
that the ILC pool is generated in different pre- and postnatal time
windows (128) and ILC precursors were also detected in human
blood (27), further research is required to investigate the relation




Developmental Stages of NK Cell
Maturation
NK cells develop from a committed NK cell progenitor (NKP) in
the BM, which was first described in 2001 based on the expression
of the IL-2/IL-15 receptor beta chain (CD122), a well-recognized
T-bet target gene (129, 130). In Figure 3A distinct developmental
and maturation stages of NK cells are described. It should be
noted that the major thrust of work on NK cell development
was performed before ILCs with an NK cell phenotype (ILC1,
subsets of ILC3) were recognized. We will critically discuss here
the conventional definition of NKPs and immature NK cells in
the new framework of ILC diversity.
An NKP population, which gave rise only to mature NK
cells but did not possess a potential for T or B-cell lineages,
was originally identified to be within Lin− NK1.1− DX5−
CD122+ cells (129). However, the frequency of such NKP
differentiating into NK cells was only one in 12 in limiting
dilution assays, revealing a highly heterogeneous population and
a requirement for additional markers to further narrow down the
true NKP, also because some T cell potential was still detectable
in this population (131). Technical progress in multicolor flow
cytometry allowed a more accurate definition of the NKP within
Lin− CD27+ CD244+ CD122− IL-7Rα+ FLT3− cells, in which
50% of the cells were giving rise to NKp46+ NK cells (132).
This NKP subset was designated as a pre-NK cell precursor
(pre-NKP), suggesting to be the earliest precursor of NK cells.
Pre-NKPs express natural killer cell receptor 2B4 (CD244) and
lack the expression of other surface markers associated with
NK cells (NKp46, NKG2D, NK1.1, or inhibitory receptors such
as Ly49 and CD94/NKG2A). Under NK cell-promoting culture
conditions, the expression of CD122 is up-regulated, thereby
giving rise to the ‘refined’ NK cell precursor (rNKP), which has
full NK cell potential (132). Apart from CD122, these precursors
also acquire during their differentiation the IL-2 receptor γc
chain, which makes NKPs responsive to IL-15, a cytokine
essential for NK cell differentiation and survival (133–135). Both
pre-NKPs and rNKPs showed the potential of differentiating
into NK cell receptor-positive cells in spleen and liver, albeit
with different frequencies. Since EOMES, a lineage-specifying
TF for NK cells was not analyzed, these studies do not allow
definite conclusions regarding a possible bipotential of NKPs
for NK cells and ILC1s. The notion that the NKP population
might contain committed ILC1 precursors was supported by
Constantinides et al., who demonstrated heterogeneity within the
pre-NKP population, with one subset expressing PLZF and other
markers characteristic for ILC progenitors and another subset
belonging to NKP (56). Therefore, more detailed analyses are
required to delineate the separation of NK and ILC1 lineages in
early precursors.
While NKG2D was already expressed by at least one subset
of NKPs, the expression of NK1.1, NKp46, and CD94/NKG2A
marked the immature NK cell stage (stage 2). The expression
of Fc receptors and Ly49s, which provide inhibitory receptors
for the NK cell education process, defines stage 3 of NK cell
development (136–139). At this stage, “NK cells” display a T-
bet signature, but since T-bet does not allow the distinguishing
between NK cells and ILC1s, the delineation between the two
lineages is difficult until EOMES and DX5 are expressed in
stage 4 (16, 21, 35, 36). Furthermore, surface markers such
as CD69, CD51, or tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL), which are often used to describe
immature NK cells, are phenotypic markers of ILC1s but not
mature NK cells in most tissues (136, 140, 141). Therefore,
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FIGURE 3 | Development of NK cells and ILC1s. (A) Developmental stages of murine conventional NK cells. Representation of markers used for the identification of
individual developmental stages. Markers highlighted in red represent those expressed mainly in the given subset and therefore important for its identification. At each
stage, the expression of the listed markers is depicted as “+”, whereas the absence of expression is indicated by “–” or alternatively “low.” (B) Tissue-specific
non-conventional NK/ILC1 subsets. Representation of markers used for the identification of non-conventional/ILC1 subsets in thymus, intestine, and liver (illustrations
created with BioRender.com).
the view that the T-bet+ EOMES− NKp46+ subset represents
immature NK (iNK) cells is currently questionable (16, 142).
T-bet+ EOMES− “NK cells” represent the major murine liver
NK-like subpopulation during fetal and neonatal developmental
stages. During aging, the ratio between these “T-bet+ EOMES−
immature NK cells” and mature NK cells changed, which
represented another argument favoring the presumption that T-
bet+ EOMES− liver “NK cells” are in fact immature NK cells
that can further mature. This hypothesis was supported by data
demonstrating that EOMES− TRAIL+ “immature” NK cells in
the adult liver gave rise to EOMES+ DX5+ NK cells (16, 142).
Contradicting results were obtained in several other publications
(21, 35, 36). Daussy et al. utilized EOMES reporter allele and
performed extensive phenotypic profiling of the EOMES-positive
and EOMES-negative populations. Even though EOMES− “NK
cells” had an “immature phenotype” and EOMES+ NK cells
had “mature” characteristics, in vivo and in vitro differentiation
experiments did not show any transition between these two
populations. PLZF fate mapping supported these results because
EOMES+ DX5+ NK cells did not derive from PLZF-expressing
progenitors, whereas EOMES− TRAIL+ populations originated
from PLZF+ precursors. In addition, EOMES− TRAIL+ ILC1s
did not differentiate into EOMES+ DX5+ NK cells (35, 36,
56). Moreover, Constantinides et al. demonstrated that ILC1s
predominate over cNK cells during development in murine
liver, while cNK cell number increases during adulthood (56).
Therefore, since ILC1s and NK cells have parallel progression
at an early stage during development and are phenotypically
similar, further analyses have to be performed to separate iNK
cells from ILC1s.
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Mature bona fide NK cell subsets are characterized by the
following: 1) expression of EOMES and DX5 (stage 4); 2)
acquisition of CD11b (stage 5); 3) the consecutive loss of CD27
(stage 6) and the up-regulation of CD43 and KLRG1 (136, 143).
Developmental intermediates were identified among CD11bhi
cells, designated as mature NK cell subsets (136). CD27 is a key
marker of the NK cell lineage, dissecting the mature CD11b+
NK cell pool into two functionally distinct subsets (144, 145).
The CD27low NK cell subset possesses a higher threshold to
stimulation and appears to be tightly regulated by the expression
of NK cell inhibitory receptors. The preceding subset is consisting
of the CD27high NK cells that display a greater effector function,
exhibiting a distinct tissue distribution and responsiveness to
chemokines and productively interacting with dendritic cells
(144, 145).
Cytokine Signals Regulating NK Cell
Development
Although NK cell commitment is not dependent on IL-2, IL-4,
IL-7, IL-9, IL-15, or IL-21, which are executing their function
through a common cytokine receptor γ chain, early NKPs have
the capacity to respond to cytokines through the co-expression
of CD122 and CD127 (146). Since mice lacking IL-2, IL-4, and
IL-7 developed normal numbers of phenotypically mature NK
cells with a regular capacity to exert natural cytotoxicity in
vitro, produce IFN-γ, and kill tumor cells in vivo (146), IL-
15 was identified as the major γc cytokine to promote NK cell
development, and it plays a dominant role in early NK cell
differentiation by maintaining normal numbers of immature and
mature NK cells in the BM and spleen (146, 147). Given that
the close association of T-box TFs and IL-15 responsiveness
via CD122 is a hallmark of many lymphocytes, including ILCs
and unconventional tissue-resident T cells (148–152), IL-15 was
also indispensable for the development of ILC1s and ex-ILC3s
although they co-express CD127 (21, 35, 153). IL-15 activated
NK cells by STAT5 signaling and promoted the expression of the
anti-apoptotic protein MCL1 and, at the same time, restricted
the expression of pro-apoptotic proteins such as BIM and NOXA
(153, 154).
Transcriptional Regulation of NK Cell
Development
NK cell development and function are regulated by a plethora
of TFs expressed at different developmental stages, and at
each stage these sets of TFs constitute regulatory networks
for the establishment of distinct phenotypes. While numerous
TFs that regulate pivotal steps during NK cell development
were identified, the regulation of NK cell development is much
less understood on a molecular level. As a consequence, the
NK cell-specific target genes of TFs are insufficiently defined.
Although TFs were proposed to mainly act during one stage of
NK cell development, it should be considered that they might
regulate NK cell development at various stages and depending
on the amount of TFs being expressed (i.e. TF gradients).
Additional difficulties in assembling the available data into a
satisfying model are represented by the limitations in accurately
recording relatively small NKP populations given the very limited
availability of multicolor flow cytometry and by the separation
of immature NK cells from ILC1s (as already discussed above).
Therefore, although supported by data, the conclusion that
certain TFs act at a certain stage of NK cell development should
be taken with caution as these analyses often pre-dated the
discovery of ILC1s and other ILC subsets expressing NK cell
receptors such as NKp46 and NK1.1. With this in mind, we will
discuss here the major TFmodules that have been associated with
NK cell differentiation.
Developmental defects in NK cells were reported from mice
deficient for the TFs PU.1 and IKAROS that are broadly
expressed early in hematopoiesis before commitment to the
ILC/NK lineage and therefore affect multiple hematopoietic
lineages, including but not limited to NK cells (155–158). Since it
is controversial if PU.1 is expressed during NK cell development
at all, it is unclear whether PU.1 or IKAROS are mediating
effects during NK cell development or whether the phenotypes
might be explained by the effects in upstream hematopoietic
precursors (159).
Various TFs, such as TCF-1, NFIL3, and TOX, that were
already introduced to regulate early commitment to the ILC
lineage are indispensable for NK cell development, likely by
acting on the EILP or upstream progenitors. Mice deficient for
either TCF-1, NFIL3, or TOX lacked NK cells and also other ILC
lineages (117, 123, 160). Since these TFs are already expressed
upstream of the NKP in multipotent ILCPs such as EILP, CHILP-
A, or CHILP-B, mice deficient in these TFs lacked most ILC
lineages. Therefore, at least some of the effects likely occur
already in multipotent precursors before commitment to the NK
cell lineage (106, 124). Whereas, the mechanistic role for TOX
after NK cell commitment is elusive, it was shown that TCF-1
restricts granzyme expression, thus protecting the developing NK
cells from self-destruction (161). While NFIL3 was recognized
as a TF important for the transition from CLPs to early ILC
precursors, it was shown to be also up-regulated in the NKP
cells. Further, its deficiency in mice led to decreased numbers of
NK cells (121, 162). While it was proposed that NFIL3 regulates
ID2 expression (117, 163), Seillet et al. showed that NFIL3
was influencing EOMES expression, whereas ID2 expression in
the absence of NFIL3 remained the same. Moreover, ectopic
expression of EOMES inNfil3−/− hematopoietic progenitor cells
was sufficient to rescue cNK cell development (162).
Mice deficient for the TF ETS-1 had a strong reduction in
mature NK cell numbers (164). Similar to NFIL3, ETS-1 was
already expressed in CHILPs and also in NKPs. ETS-1 regulated
the fitness of CHILPs, but the effects on NK cell development are
probably emerging later with reduction at pre-NKP and rNKP
stages, where ETS-1 might regulate T-bet and ID2 (165, 166).
MEF is another member of the ETS TF family, which regulated
essential functions during NK and NKT cell development,
whereas B and T cells developed in normal proportions (167).
While MEF-deficient mice have reduced NK cells and impaired
effector function, including cytotoxicity and IFN-γ production,
mechanistic insights are scarce (167).
Important regulators of NK cell development include ID2 and
GATA-3, known to regulate early ILC commitment (21, 125).
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However, due to the phenotype of the gene-deficient mice and
their expression pattern, it seems more likely that these TFs
mediate their decisive effects after NK cell commitment. Mice
deficient in ID2 or GATA-3 developed NKPs and immature
NK cells but had a maturation defect of NK cells. In contrast,
they lacked the other ILC lineages (12, 28, 105, 109, 126).
While GATA-3 is required for ILC1 development (21, 28, 168,
169), it was dispensable for the development but not for the
maturation of NK cells. GATA-3-deficient NK cells had an
immature phenotype, were poor producers of IFN-γ, and showed
defects in BM egress because they are retained in the BM due
to the high CXCR4 expression (28, 126, 169). ID2 represents
another transcriptional regulator that was up-regulated during
NK cell development from NKPs and that was essential for
the development of mature NK cells (105, 109, 162). Notably,
unlike other ILC populations, NKPs and immature NK cells
developed in ID2-deficient mice. However, ID2 deficiency causes
loss of terminally differentiated CD11b+ NK cells, indicating a
persistent need for the sequestration of E-proteins during NK
cell maturation (170, 171). In support of this notion, the genetic
deletion of ID2 and ID3, which both bind E-proteins, resulted
in the complete loss of NK cells. It was also proposed that ID2
regulates IL-15 receptor signaling via the suppression of SOCS3.
Interestingly, both ID2 and IL-15 signaling were linked to the
regulation of apoptosis in NK cells via either anti-apoptotic
MCL1 or pro-apoptotic BIM (154, 170, 172). Therefore, ID2
could be a link between sensing of the vital cytokine IL-15 and
cell survival.
Several TFs with a more restricted expression during
hematopoiesis played pivotal roles during the maturation of NK
cells. These include EOMES, T-bet, and ZEB2. Unlike ILC1s,
which only expressed and were developmentally dependent on
T-bet but not EOMES, mature NK cells co-expressed both T-
bet and EOMES. While mice with a conditional deletion of
EOMES lacked NK cells, these cells normally differentiated in
T-bet-deficient mice where they were accumulating in the BM
and the lymph nodes due to the altered expression of S1P5R and
CXCR3. They displayed an immature phenotype characterized
by the persistent expression of CD27 and the reduced CD11b,
CD43, and KLRG1 levels (33, 34, 173, 174). A similar NK cell
maturation phenotype was reported from mice deficient in the
Zinc finger-containing protein (ZEB2) (175). The notion that
ZEB2 and T-bet might cooperatively regulate NK cell maturation
is also supported by data showing that the overexpression of
ZEB2 can partially rescue the phenotype of T-bet-deficient NK
cells (175).
Although EOMES is also expressed by non-hematopoietic
cells as well as in CD8+ T cells, where the TF regulates CD8
memory formation, among ILCs, EOMES represents a specific
TF for NK cells (16, 176, 177). Moreover, mice harboring a
conditional deletion of EOMES using NKp46Cre completely
lacked NK cells but still contain other ILC lineages (178,
179). Therefore, EOMES represents an attractive candidate
for the specific targeting of NK cells by using, for example,
NKp46Cre Eomesfl/fl mice to exclude effects on T cells. While
epigenetic studies provide evidence that the EOMES and the
T-bet promoters are both in an open chromatin configuration
in NK cells, downstream targets of the T-box TFs are not
well-defined in NK cells and were largely extrapolated from
studies that have investigated other cell types (180). However, the
importance of EOMES in NK cell fate and in the expression of
prototypic markers of NK cells is also illustrated by data showing
that the overexpression of EOMES under the Tbx21 regulatory
elements reprogrammed ILC1s to adopt phenotypical hallmarks
of NK cells (178). Since the down-regulation of EOMES in NK
cells mediated by TGF-β drove the NK cells to adopt an ILC1
phenotype, EOMES appears as a major signaling hub that dictate
NK cell identity (181, 182).
Numerous TFs including AIOLOS, PRDM1 (BLIMP1),
FOXO1, IRF2, RUNX3, and KLF2 regulate the late
developmental stages of NK cells with main effects on terminal
maturation and effector functions. PRDM1 (encoding BLIMP1)
was shown to be regulated by T-bet and IL-15. Further, BLIMP1-
deficient mice had fewer KLRG1+ mature NK cells. Although
granzyme B expression was altered in PRDM1-deficient NK
cells, effector functions, including cytotoxicity, remained normal
(183). A similar phenotype was reported for mice deficient in the
IKAROS zinc finger TF member AIOLOS. NK cells developed in
AIOLOS-deficient mice but terminally differentiated CD11b+
NK cells were reduced. While NK cell effector functions were
largely maintained, Aiolos−/− NK cells were hyper-responsive to
tumor cells, resulting in superior tumor surveillance (184).
The conditional deletion of the Krüppel-like TF KLF2
in hematopoietic cells using VavCre resulted in the ablation
of mature CD11b+ NK cells and consequently reduced the
cytotoxicity toward target cells (185). It was proposed that KLF2
regulates the survival of NK cells via the regulation of IL-15
sensing and the expression of homing receptors. Reduced NK
cells were also reported from mice deficient in the Th1 regulator
interferon regulatory factor 2 (IRF-2) (186). IRF-2 deficiency
disturbed mainly mature splenic NK cells, whereas NK cell
development in the BM was only mildly affected. IRF-2 NK
cells were more prone to undergo apoptosis during development
independently from IL-15 (187).
TFs regulating NK cell development involves FOXO proteins
as well. However, the precise role is hard to evaluate because of
data that are difficult to reconcile with a model. WhileWang et al.
found decreased numbers of NK cells in mice with conditional
deletion of FOXO1 using NKp46Cre deleter mice (188), Deng
and colleagues reported increased numbers of mature, hyper-
reactive NK cells using NKp46Cre and also VavCre deleter mice
to genetically ablate FOXO1 (189, 190).
Runt-related TFs (RUNX) are important regulators of
lymphocyte development, including T cells and several ILC
lineages. RUNX members 1–3 form heterodimers with the TF
core-binding factor beta (CBF-β) in order to bind to regulatory
DNA sequences and mediate gene transcription (191, 192).
The RUNX3 isoform is highly expressed in NK cells. Different
strategies were used to genetically interfere with RUNX to
investigate the function in vivo, including the overexpression
of dominant-negative RUNX3 or the conditional deletion of
RUNX3 or CBF-β. While RUNX3 regulated the development of
ILC1s and ILC3s by different mechanisms, ILC2 development
remained intact and RUNX proteins protected ILC2s from
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an exhaustion-like phenotype (192–194). Concerning NK cell
development, the deletion of either RUNX3 or CBF-β altered
NK cell development via the regulation of CD122 and IL-
15 responsiveness. This was accompanied by reduced numbers
of CD11b+ and CD43+ mature NK cells and enhanced
cytokine production (195–197). Consistent with a role later in
development, RUNX and CBF-β were also crucial for NK cell
memory formation following MCMV infection (198).
Finally, TFs that constitute regulatory network during NK cell
development represent a nice example of how these proteins act
as a part of a complex context that dictates their function and
how compensatory mechanisms in their absence could, in some
situations, buffer the entire system.
DEVELOPMENT OF
ILC1s/TISSUE-RESIDENT NK CELLS
NK cells and ILC1s share many phenotypical and functional
properties that make the differentiation between these two innate
lymphocyte subsets, especially in humans, very challenging (59).
In addition, ILC1s comprise several subsets of lymphocytes
previously referred to as “immature,” “tissue-resident,” or
“unusual” NK cells before the revised nomenclature in 2013.
These include TRAIL+ NK cells (142) and thymic NK cells (168)
or (after the revised nomenclature) ILC1s in the BM, the lamina
propria (21), the epithelium of the intestine [intraepithelial
(ie)ILC1s] (20), the salivary glands (199), the adipose tissue (200),
or the uterus (201). ILC1 subsets differ in terms of dependency on
TFs during development, e.g. EOMES and NFIL3, and cytokines,
e.g. IL-7 and IL-15 (21–23, 36, 120, 168, 202). Although these
subsets are often all referred to as ILC1s, it is very difficult to
conclude whether different developmental requirements reflect
the tissue adaption of one cell lineage or different cell lineages
of phenotypically similar cells. Besides the heterogeneity and
the tissue adaptation of ILC1s, differences between mouse and
human ILC1s add an additional layer of complexity to the topic.
For example, it is well-established that murine liver TRAIL+ NK
cells express and are developmentally dependent on T-bet but
not EOMES. However, the human liver contains a population of
CD56bright lymphocytes, which phenotypically resembled ILC1s
but expressed high levels of EOMES and only low levels of
T-bet (203). Nevertheless, the functional and the phenotypical
characterizations of different subsets of ILC1s are contributing
to a better understanding of their biology and diversity as well
as enabling their separation in a more comprehensive way.
While being recognized as tissue-resident cells, ILC1s have been
residing in various tissues, expressing specific markers that are
represented in Figure 3B and which will be discussed below.
The characteristic feature of thymic non-conventional
NK/ILC1 is that they express CD127 and developmentally
depend on IL-7 signaling (168). This is in contrast to splenic
and BM cNK cells, the phenotype and the function of which
were not perturbed in the absence of IL-7. To a lesser extent,
thymic NK cells required IL-15 for their development similar
to NK cells (204). Moreover, thymic non-conventional NK cells
depended on GATA-3 for their development and showed an
elevated expression of this TF in comparison to splenic cNK cells
(168). Phenotypically, thymic NK cells resembled ILC1s rather
than NK cells because of the lack of CD11b and Ly49 receptors
and their expression of CD69. However, whether thymic NK
cells belong to the same lineage as ILC1s and TRAIL+ liver NK
cells requires further clarification, especially because they express
EOMES and DX5, which are usually not found on ILC1s (202).
Thymic NK cells were reduced in Foxn1−/− mice, which do
not develop a functional thymus, suggesting that the thymus is
an organ required for the generation of this ILC1 subset. Data
obtained in reporter mice for TCR-δ germ-line transcription
suggest that thymic NK cells might be derived from lymphocytes
with T cell potential (205). This is in line with data showing that
primitive, double-negative T cell progenitors still possess the
potential to differentiate into cells that phenotypically resemble
NK cells (206). Further, it was proposed that thymic NK cells
might be the counterpart of CD56bright NK cells, which are
potent IFN-γ producers but have weak cytotoxic potential (168).
Based on CD56 expression, a unique subset of ILC1s was
also described in the intestinal epithelium of humans. NKp44+
CD103+ and NKp44− CD103− ieILC1s were discriminated with
similar functional properties, such as strong IFN-γ production.
In addition, ieILC1s showed signs of TGF-β imprinting, such
as CD103 expression, and were phenotypically different from
cNK cells as illustrated by the expression of CD160, CD49a,
CXCR6, CD69, and CD39, which were also found on ILC1s in
other organs (141). Unlike thymic NK cells, ieILC1s lacked the
expression of CD127 (IL-7Rα) but did express IL-2Rβ chain.
The murine counterpart of human ieILC1s localizing within the
gut epithelium co-expressed CD160, NKp46, and NK1.1 (20).
Examining the developmental pathway of ieILC1s in mice, Fuchs
et al. demonstrated the requirement of NFIL3 and T-bet. These
ieILC1s were in part independent of IL-15Rα, indicating that
intraepithelial ILC1s are developmentally distinct from cNK cells
(20). Functionally, and similar to ex-ILC3s, ieILC1s were linked
to the immunopathology in the αCD40 model of colitis due
to their IFN-γ production (20, 52, 207). Further, ILC1s were
enriched in patients with Crohn’s disease and may, therefore,
contribute to the development of inflammatory bowel disease
similar to lamina propria ILC1s (19, 20, 208).
In the lamina propria of the intestine, it was challenging to
identify ILC1s because of the sizeable populations of NK cells and
ex-ILC3s, which all expressed the prototypic makers of ILC1s,
such as NKp46 and NK1.1. Using double-reporter mice for
EOMES (labeling NK cells) and fate-labeling for RORγt (labeling
all ILC3s independent of their RORγt expression), a subset of
lymphocytes within NKp46 and NK1.1 lymphocytes was defined,
which expressed T-bet. This population within NKp46+ NK1.1+
lymphocytes lacked EOMES and RORγt expression and did not
have a history of RORγt expression either. Further, such ILC1s
were developmentally dependent on T-bet, NFIL3, and GATA-
3, but not EOMES or RORγt. Phenotypically, intestinal ILC1s
expressed markers associated with ILC1s in different tissues
such as CD127, CD160, or CD49a, lacked markers of cNK cells
such as CD11b and CD62L, and showed low Ly49 receptor
expression. Despite expressing both CD127 and CD122, ILC1s
were strictly IL-15-dependent and did not require IL-7. Upon
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transfer into alymphoidmice, ILC1s were a stable lineage without
differentiation potential into cNK cells or ex-ILC3s and could
also be found in the BM (35). BM ILC1s phenotypically overlap
with the previously described immature NK cells based on
markers such as CD69 (140). However, markers often connected
to immature NK cells, such as CD69, TRAIL, or CD51, are
rather found on ILC1s, and it should also be noted that they are
not expressed before or after that developmental stage during
NK cell development. In addition, CD69 is considered to be a
marker for cell activation or tissue residency, which is associated
with activated rather than with immature lymphocytes (136,
140). Therefore, additional studies have to address the potential
heterogeneity within EOMES− NK1.1+ cells, previously termed
“immature NK cells” in the BM.
Although cytokine IL-12 was first described as a NK cell-
stimulating factor (209), IL-12 elicited stronger effects on ILC1s
than on NK cells, consistent with higher expression levels of
the components of IL-12 receptor on ILC1s (21, 62, 210). While
ILC1s were potent producers of IFN-γ and TNF, they expressed
less perforin, indicating that they are less cytotoxic and rather
mediate the cytotoxic effect by TNF receptors such as TRAIL.
Functionally, a lack of perforin-mediated cytotoxicity or a loss
of NK cell identity resulted in decreased immunosurveillance of
tumors (181, 182, 211). However, data from different infection
models suggest that there is a spatial and a temporal division of
labor between NK cells and ILC1s. ILC1s protected the digestive
tract from Toxoplasma gondii, Clostridium difficile, or MCMV
infections, which are controlled to a large degree by IFN-γ
secreted by ILC1s (21, 210, 212).
ILC1s, also referred to as tissue-resident NK (trNK) or
TRAIL+ NK cells in the liver (142), differed from conventional
NK cells since they expressed only T-bet as the key TF in mice,
and this expression is favored in the liver microenvironment
(16, 29, 35, 36). On the contrary, the BM provides a
microenvironment that promotes lower expression levels of T-bet
in NK cells, enabling the subsequent expression of EOMES (35).
Another remarkable difference between cNK cells and ILC1s was
the expression of the “homolog of BLIMP1 in T cells” (HOBIT) in
ILC1s (213). This TF is specifically up-regulated in tissue-resident
cells and controlled the expression of molecules associated
with tissue residency, such as CD49a and CD69. Interestingly,
HOBIT was essential for liver ILC1s but not for ILC1s in other
organs investigated (210, 213). In addition, the development
of ILC1s in the liver was demonstrated to be dependent on
PLZF expression and independent of NFIL3, contrary to NK
cells (36, 98).
TRAIL represents a prototypic marker of liver ILC1s as it
is constitutively expressed on both mouse and human ILC1s,
and together with CD49a and CD69, it has been used for
separating liver ILC1s fromNK cells. This type II transmembrane
protein causes apoptosis primarily in tumor cells by binding
to certain death receptors. Recent findings are suggesting that
TRAIL expression is regulated by the activation of the NKp46
receptor in ILC1s since NKp46-deficient mice lack this effector
protein (214–216).
Another important functional hallmark of liver pro-
inflammatory ILC1s is that they are activated via IL-12,
which are produced by conventional dendritic cells upon
infection. After activation with IL-12, ILC1s respond with IFN-γ
secretion to limit viral load and thereby contribute to early
antiviral immunity at sites of primary viral infection (210).
The genetic ablation of liver ILC1s is leading to increased
MCMV load in mice; hence, NK cell responses are not the
only early antiviral response in mice. In addition to rapidly
responding to IL-12, “memory-like” qualities have been
reported for ILC1s in models of contact hypersensitivity
and MCMV infection. This is remarkable because these
cells were originally considered as “immature NK” cells due
to the lack of surface markers characteristic of mature NK
cells (142). ILC1s were described to mediate tissue-resident
memory responses to MCMV depending on glycoprotein m12
(217). Furthermore, previous reports have already linked liver
ILC1s to memory responses during contact hypersensitivity
reactions (29, 218). However, the mechanism underlying
recognition of haptens by ILC1s following memory responses
remains elusive.
Taken together, the experimental evidence obtained from
knockout mice suggests that ILC1s constitute a separate tissue-
resident lineage distinct from cNK cells. Further investigation is
required to answer questions of ILC1 diversity.
EPIGENETIC AND microRNA-MEDIATED
REGULATION OF NK CELL AND ILC1
DEVELOPMENT
Among epigenetic modifications, the deubiquitination of histone
H2A by MYSM1 is important for NK cell generation as the
deletion of this enzyme is causing maturation defects in NK
cells (219). The MYSM1 histone H2A deubiquitinase also
contributed to the development of ILC1s in other organs.
In addition to modifying histones, MYSM1 also functions
as a transcriptional regulator of ID2 expression during the
maturation of NK cells by recruiting NFIL3 to the Id2 gene
locus. MYSM1 was involved in maintaining an active chromatin
configuration at the Id2 locus (219), further promoting its
expression. Another epigenetic mechanism that regulates NK cell
development involves repressive histone marks such as the tri-
methylation of lysine residue 27 of Histone 3 protein during
early NK cell differentiation (220). In the absence of this marker
through the repression of EZH2 enzymatic activity (enhancer
of zeste homolog 2), ILC1 and NK cell lineage commitment
was enhanced, together with increased NK cell survival and
NKG2D-mediated cytotoxicity (220).
Apart from the regulation of gene expression on the
transcriptional level, another epigenetic mechanism is required
for the proper development of ILC1s and the adequate
maturation of NK cells. Available data implicate small non-
coding RNA molecules (221–226), such as microRNAs (miRs),
to regulate posttranscriptional gene expression by binding to
the 3′ untranslated region (UTR) of mRNAs and inducing
either suppression or mRNA translation or its degradation (227).
Deletion of the RNase III enzyme Dicer-1, an enzyme required
for the generation of single-stranded 20–25 bp long non-coding
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RNA molecules, in NKp46-expressing cells revealed the role
of miRs in murine NK cells and ILC1s (223). The number of
NK1.1+ cells in the organs of Dicer-1 mutant mice was affected,
along with the impaired maturation of NK cells. NK cells without
miR showed a diminished function, including reduced target
cell cytotoxicity and IFN-γ production. Additionally, in Dicer-
1-deficient mice, the IL-15 receptor signaling in NK cells was
impaired. This finding explains, at least in part, the decreased
survival of NK cells and the observed perturbations in NK
cell maturation.
The effects of single miRs, such as miR142, miR155, miR150,
andmiR15/16, revealed specific effects and potential target genes.
The conserved miR142 sequence encodes two highly expressed
maturemiRNAs, 142-3p and 142-5p, which have different mRNA
targets (221). The target of the miR142-3p is the 3′ UTR of
Itgav gene that encodes integrin-αV. In the absence of miR142-
3p, this integrin was up-regulated in ILC1s and promoted their
survival. The other product of themiR142 sequence, miR142-5p,
was targeting the 3′ UTR suppressor of cytokine signaling 1 (Socs1)
gene, a negative regulator of IL-15 signaling. Thus, in the absence
of miR142-5p, SOCS1 un-antagonized, leading to impaired IL-15
signaling (221).
In humans, miR155 was shown to down-regulate SH2
containing 5′ inositol phosphatase (SHIP1), which in part
contributes to the regulation of IFN-γ production following
stimulation (225). In mice, miR155 targeted the 3′ UTR of Noxa
transcripts during homeostasis and of Socs1 transcripts during
the activation of NK cells (226). The direct functional target of
miR-150 and miR15/16 was the TF c-Myb, through which the
maturation program was controlled (222, 224).
PLASTICITY TOWARD GROUP 1 ILCs
Although ILCs comprise separate lineages of innate lymphocytes
defined by distinct lineage-specifying TFs, a considerable amount
of plasticity after fate commitment was reported for most ILC
lineages in mice and humans, often connected to a certain
tissue microenvironment or in the context of inflammation
(228). Plasticity is characterized by the down-regulation of
lineage-specifying TFs, such as RORγt for ILC3s or GATA-
3 for ILC2s, and acquisition of master TFs of alternative
cell fates, acquisition of phenotypic characteristics of other
ILC lineages (e.g. up-regulation of NK cell receptors), and
production of cytokines not associated with the original lineage.
The plasticity of ILCs was first described for ILC3s (52, 229).
Fate-labeling for RORγt expression revealed that ILC3s were
able to differentiate into cells phenotypically resembling ILC1s
(referred to as ex-RORγt+ ILC3s or ex-ILC3s) (52, 229–231).
This process was accompanied by the gradual up-regulation
of ILC1 signature genes such as T-bet, NK receptors (NKp46,
NK1.1, and NKG2D), and cytokine receptors (IL12Rβ2), as
well as effector functions (19, 21, 44, 53, 55). During this
process, ex-ILC3s became IFN-γ-producing lymphocytes, which
were responsive to several cytokines, including IL-12 and IL-
23, and promoted inflammation and immunopathology in
experimental models of colitis and Salmonella enterica infection
(44, 52, 207, 229, 232, 233). T-bet deficiency was vice versa
reported to promote colitis in response toHelicobacter typhlonius
that was mediated by IL-17A-producing ILC3s (234, 235). In
humans, differentiation of ILC3s toward CD127+ ILC1s was
described in the intestine of patients with Crohn’s disease
and was promoted by cytokines IL-2 and IL-12 and CD14+
DCs. Interestingly, this process was found to be reversible
and stimulated by IL-1β, IL-23, retinoic acid, and CD14−
DCs (19, 229, 230). Data obtained in fate-labeling studies in
mice using either RORγ tCre (230) or NKp46Cre (236) also
support the model that the plasticity of ILC3s is a reversible
process. Signals regulating NKp46 expression on CCR6− ILC3s
included the Notch-T-bet axis as a positive regulator and TGF-
β signaling as a negative regulator (236). Altogether these
studies provide evidence for the reversible plasticity of CCR6−
ILC3s toward ILC1s, mediated by signals that regulate RORγt
and T-bet.
While the down-regulation of RORγt and the up-regulation
of T-bet occurs at steady state in CCR6− ILC3s, the plasticity
of NK cells or ILC2s might require a trigger, such as
chronic inflammation. The conversion of ILC2s to an ILC1-like
phenotype is triggered by cytokines, such as IL-1, IL-12, and
IL-18, and was described in the context of chronic obstructive
pulmonary disease (237–240). This process is connected to the
up-regulation of T-bet, and the genetic deletion of T-bet using
NKp46Cre resulted in enhanced ILC2 responses, suggesting that
the balance of the lineage-specifying TFs GATA-3 and T-bet
determines ILC2 plasticity (241).
Whether the conversion of NK cells to ILC1-like cells is
occurring at a steady state is difficult to evaluate because of
the lack of fate-labeling studies for the NK lineage-specifying
TF EOMES. However, fate-labeling was carried out using Cre
under the NKp46 promoter, which is expressed in NK cells,
ILC1s, CCR6− ILC3s, and subsets of γδ T cells (138). While
the down-regulation of NKp46 was described for ILC3s (236),
the results did not provide evidence that NK cells down-regulate
NKp46 at steady state (138). It should be considered though that
conversion in other ILC lineages, which also express NKp46,
would not be detected using this fate-labeling strategy. The
first evidence for the potential conversion of NK cells into
ILC1-like cells came from studies that investigated the unusual
subsets of ILC1s in the salivary gland. Unlike ILC1s in other
organs, the salivary gland ILC1s co-expressed EOMES and T-
bet but did not developmentally depend on either of these TFs
and also not on NFIL3, suggesting that they have different
developmental requirements (199, 242). In addition, the salivary
gland ILC1s depicted hallmarks of tissue-resident cells, such as
TGF-β imprinting, that was also reported for ILC1s in different
organs, for instance, the intestine (20). ILC1s in the salivary
gland were reduced in the absence of TGF-β signaling, and
the phenotypical markers of ILC1s, such as CD49a and TRAIL
were down-regulated, whereas EOMES was up-regulated (199).
Furthermore, NK cells that were hyper-responsive to TGF-β,
due to the genetic manipulation of TGF-βRI or deletion of
SMAD4, developed an ILC1-like phenotype in the salivary gland
or within tumor tissue. As a consequence, these ILC1-like NK
cells failed to control tumor growth or viral infection with
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cytomegalovirus (181, 182). Some of the effects that TGF-β has
on the NK/ILC1 fate decisions are mediated via the balance of
the master TFs T-bet and EOMES. Notably, it was reported that
the forced expression of EOMES driven by the T-bet promoter
turned ILC1s into cells with NK cell properties (178). However,
it remains unclear whether this occurs in vivo, and if yes, under
which conditions.
While ILC plasticity after lineage commitment is now
well-established to occur, additional investigation is required
to elucidate how the plastic behavior of ILCs could be
therapeutically harnessed.
SPECIFIC TARGETING TO UNCOVER
FUNCTIONAL SPECIALIZATION OF
GROUP 1 ILC SUBSETS
Despite progress in the generation of genetically modified mice,
specific targeting of ILCs remains a major challenge in the field
because of the large overlap in gene expression between ILCs
and T cells as well as other immune cells. Since a systematic
review of genetic models for the investigation of ILC function
was recently published (243), we aim to focus the discussion
on NK cell receptor (NKR)+ ILCs that comprise conventional
NK cells, ILC1s, and CCR6− ILC3s. Concerning NKR+ ILCs,
specific targeting of each subset is further complicated by shared
receptors such as NKG2D, NKp46, and NK1.1 and TFs such
as T-bet, NFIL3, or TOX within NKR+ ILCs, making them
alone not a suitable target (141). While antibody-mediated
depletion strategies using αNK1.1 or αThy1 were effective,
more specific depletion strategies were developed using genetic
models based on NKp46Cre mice (138, 153, 244). While NKp46
is fairly specific to group 1 ILCs, a second allele is required
to ensure specificity among group 1 ILCs, which is often a
floxed mouse for an essential TF such as EOMES or RORγt.
Following the targeting strategy, the generation of NKp46Cre
Eomesfl/fl resulted in the selective ablation of NK cells, thus
allowing a definitive conclusion about the contribution of NK
cells in an experimental autoimmune encephalomyelitis model
(178, 179). NKp46Cre Rorc(γt)fl/fl mice were likewise generated
to investigate redundant and non-redundant functions of ILC3s
during Citrobacter rodentium infection and in colitis models
(233, 245). While these two strains provide specific targeting
for NK cells and CCR6− ILC3s, respectively, the genetic mouse
models for ILC1s are even more difficult to develop. NKp46Cre
Tbx21fl/fl mice lacked ILC1s (179), but a contribution of NK cells
or CCR6− ILC3s in these mice could not be excluded because
NK cells and CCR6− ILC3s have a migration or maturation
defect in T-bet-deficient mice. It should be also considered that
the phenotype might be dependent on which line of NKp46Cre
deleter mice is used (179, 241). Furthermore, mice deficient for
the TF HOBIT were used to investigate ILC1 function in the liver
because ILC1s, but not NK cells, are reduced in the liver of these
mice. However, the use of this mouse line is limited to TRAIL+
NK cells and not ILC1s in other organs (210, 213). Therefore,
the goal for NKp46Cre to delete a selective TF important for ILC1
subsets in many organs is still not achieved.
REGULATION OF NK CELL
DEVELOPMENT AND FUNCTION BY
RECEPTOR–LIGAND INTERACTION
The activation of NK cells is mediated to a large degree by the
integration of stimulatory and inhibitory signals as measured
by the engagement of NK receptors by its cognate ligands.
NK cells need to be calibrated during development to become
activated if a defined threshold of stimulatory to inhibitory
signals is exceeded, a process coined “NK cell education”
or “licensing.” Classical NK cell education is linked to self
recognition and mediated by inhibitory receptors for class I
MHC, such as Ly49 receptors or KIR (82, 246–248). Thus, this
process requires the timely expression of the corresponding
ligands for the receptors involved in the education process.
Moreover, besides the type of MHC molecule expressed and the
type of receptors on NK cells, the strength of class I MHC–
Ly49 receptor interaction also defines the quality and the quantity
of NK cell education (249). In connection with this, it was
observed that the absence of MHC I on the surface of cells, by
the genetic deletion of β2-microglobulin, TAP, or K
bDb, resulted
in the hypo-responsiveness of NK cells (250–252). In line with
these findings, NK cells with mutations in ITIMs required for
inhibitory signaling were functionally impaired. Further, the
deletion of intracellular downstream signaling molecules, SH-
2-domain-containing protein tyrosine phosphatase 1 (SHP1)
and SH-2-domain-containing inositol-5-phosphatase (SHIP),
resulted in the hypo-responsiveness of NK cells (253–255). On
a molecular level, the MHC I education process was linked to
the reorganization of the nanostructure of immunoreceptors and
confinement in domains, thus generating the basis for different
activation thresholds (251, 252, 256).
Interestingly, Ly49s were strongly underrepresented but not
totally absent on ILC1s, suggesting differences between NK
cell and ILC1 education. However, with respect to ILC1s,
fundamental questions remain unanswered. These questions
include whether ILC1s require an education process at all
and, if so, whether the education is regulated by cell-bound
immunoreceptor–ligand interaction. If this is true, how much
of education is regulated by inhibitory receptors such as
CD94/NKG2A expressed by ILC1s? Due to the lack of data
for ILC1 education, we focus on the regulation of NK cell
development and activation (21, 141).
NK cell education not only is limited to self recognition
of MHC I molecules but also involves self recognition of
non-MHC ligands such as those provided by the receptor–
ligand pairs CD155-TIGIT, CD48-2B4, and CLR-b-NKRP1-B
(252). Moreover, it became apparent that stimulatory receptors
mediating induced-self recognition are involved in the NK cell
education process as well. NKG2D is a stimulatory receptor,
which recognizes induced-self ligands and which regulates NK
cell education (90). NKG2D is already expressed early on
from the NKP stage. For induced-self ligands, it is however
incompletely understood when these ligands are expressed under
homeostatic conditions and which cell types would be involved
in this process (132, 257, 258). Parallel to the finding that
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NK cells from MHC I-deficient mice were hypo-responsive,
a similar paradoxical phenotype was uncovered for NKG2D-
deficient mice having hyper-responsive NK cells despite the
lack of an important stimulatory NK cell receptor. Notably,
mice deficient for NKG2D (Klrk1−/−) were hyper-responsive,
resulting in the superior control of MCMV infection and tumor
growth (257, 258). However, immunosurveillance of tumors
expressing NKG2D ligands was impaired in NKG2D-deficient
mice (259). Mechanistically, NKG2D regulated signaling via the
natural cytotoxicity receptor NKp46 and the signaling molecule
CD3ζ (258). While the precise timing of NK cell education is not
well-defined, some studies suggested that NK cell education is
not limited to a time window during development but represents
a continuous process. This is supported by studies that used
adoptive transfer of uneducated NK cells in MHC I-sufficient
hosts that could restore NK cell functionality (260, 261). In
addition, data obtained in models that overexpressed ligands
for stimulatory receptors such as m157 or NKG2D ligands,
in which the NK cells were persistently exposed to a receptor
engagement, revealed that NK cells adapted to this stimuli, for
instance by the down-regulation of the stimulatory receptor
(262–264). Although it remains elusive if the adaptation of
NK cell reactivity to sustained activation by stimulatory ligands
due to overexpression is the underlying similar mechanism
described for NK cell education, the findings become relevant
in the context of anti-tumor immunity where, for instance,
NKG2D ligands might be continuously expressed or shedded
from the tumor cells, thus saturating their receptors. Although it
is controversial if the chronic expression or shedding of NKG2D
ligands should be regarded as a tumor escape mechanism or if it
is promoting tumor immunosurveillance, these findings indicate
the importance of the regulation of NK cell activity by receptor–
ligand interaction (265–267). Apart from the chronic expression
of induced-self ligands on tumor cells, blocking antibodies for
inhibitory receptors targeting KIR or NKG2A are evaluated
in clinical trials to promote anti-tumor immunity (267). The
blockade of inhibitory receptors on NK cells has the potential
to complement T cell immunotherapy because the efficiency of
T cell checkpoint blockade correlated with the production of
neoantigens by tumor cells present on MHC I. However, the
tumor cells that did not produce neoantigens or escaped MHC
I-peptide recognition by CD8+ T cells (268) could be recognized
and lysed byNK cells expressing inhibitory receptors to detect the
presence of MHC I. However, data available so far might indicate
that there is a narrow therapeutic window defined by the blocking
of the inhibitory receptor and the effects on NK cell education,
rendering the cells hypo-responsive (267).
In summary, NK cells need education mediated by the
engagement of inhibitory and stimulatory receptors during
development. NK cell education is required for both adequate
reactivity and tolerance toward self. Blocking of inhibitory
NK cell receptors during anti-tumor therapy can complement
checkpoint blockade and illustrates the transfer of basic
knowledge for human therapy.
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.
FUNDING
This work was supported by grants from the German Research
Foundation (DFG; KL 2963/1-1 and KL 2963/2-1 to CK) and the
European Research Council (ENTRI to CK).
ACKNOWLEDGMENTS
We thank Dr. Divija Deshpande, Dr. Katja Jarick, Caroline
Tizian, and Akriti Kanth for critically reading the manuscript.
The figures were created with BioRender.com.
REFERENCES
1. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic
reactivity of mouse lymphoid cells against syngeneic and allogeneic
tumors. II characterization of effector cells. Int J Cancer. (1975) 16:230–9.
doi: 10.1002/ijc.2910160205
2. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity
of mouse lymphoid cells against syngeneic and allogeneic tumors. I
distribution of reactivity and specificity. Int J Cancer. (1975) 16:216–29.
doi: 10.1002/ijc.2910160204
3. Kiessling R, Klein E, Pross H, Wigzell H. “Natural” killer cells in the
mouse. II cytotoxic cells with specificity for mouse Moloney leukemia
cells characteristic of the killer cell. Eur J Immunol. (1975) 5:117–21.
doi: 10.1002/eji.1830050209
4. Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I
cytotoxic cells with specificity for mouse Moloney leukemia cells specificity
and distribution according to genotype. Eur J Immunol. (1975) 5:112–7.
doi: 10.1002/eji.1830050208
5. Pross HF, Baines MG. Spontaneous human lymphocyte-mediated
cytotoxicity againts tumour target cells. I the effect of malignant disease. Int
J Cancer. (1976) 18:593–604. doi: 10.1002/ijc.2910180508
6. Mebius RE, Rennert P, Weissman IL. Developing lymph nodes collect
CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells,
and follicular cells but not T or B cells. Immunity. (1997) 7:493–504.
doi: 10.1016/S1074-7613(00)80371-4
7. Satoh-Takayama N, Vosshenrich CA, Lesjean-Pottier S, Sawa S, Lochner M,
Rattis F, et al. Microbial flora drives interleukin 22 production in intestinal
NKp46+ cells that provide innate mucosal immune defense. Immunity.
(2008) 29:958–70. doi: 10.1016/j.immuni.2008.11.001
8. Cella M, Fuchs A, VermiW, Facchetti F, Otero K, Lennerz JK, et al. A human
natural killer cell subset provides an innate source of IL-22 for mucosal
immunity. Nature. (2009) 457:722–5. doi: 10.1038/nature07537
9. Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, Grogan JL, et al.
Human fetal lymphoid tissue-inducer cells are interleukin 17-producing
precursors to RORC+CD127+ natural killer-like cells.Nat Immunol. (2009)
10:66–74. doi: 10.1038/ni.1668
10. Luci C, Reynders A, Ivanov Ii, Cognet C, Chiche L, Chasson L, et al.
Influence of the transcription factor RORgammat on the development of
NKp46+ cell populations in gut and skin. Nat Immunol. (2009) 10:75–82.
doi: 10.1038/ni.1681
11. Sanos SL, Bui VL, Mortha A, Oberle K, Heners C, Johner C, et al.
RORgammat and commensal microflora are required for the differentiation
Frontiers in Immunology | www.frontiersin.org 16 July 2020 | Volume 11 | Article 813
Stokic-Trtica et al. NK and ILC Development
of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol. (2009)
10:83–91. doi: 10.1038/ni.1684
12. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto
H, et al. Innate production of T(H)2 cytokines by adipose tissue-
associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. (2010) 463:540–4.
doi: 10.1038/nature08636
13. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al.
Nuocytes represent a new innate effector leukocyte that mediates type-2
immunity. Nature. (2010) 464:1367–70. doi: 10.1038/nature08900
14. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, et al.
Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc
Natl Acad Sci USA. (2010) 107:11489–94. doi: 10.1073/pnas.1003988107
15. Mjosberg JM, Trifari S, Crellin NK, Peters CP, Van Drunen CM, Piet B, et al.
Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined
by expression of CRTH2 and CD161. Nat Immunol. (2011) 12:1055–62.
doi: 10.1038/ni.2104
16. Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, Sun JC, et al.
The transcription factors T-bet and Eomes control key checkpoints
of natural killer cell maturation. Immunity. (2012) 36:55–67.
doi: 10.1016/j.immuni.2011.11.016
17. Hoyler T, Klose CS, Souabni A, Turqueti-Neves A, Pfeifer D, Rawlins
EL, et al. The Transcription factor GATA-3 controls cell fate and
maintenance of Type 2 innate lymphoid cells. Immunity. (2012) 37:634–48.
doi: 10.1016/j.immuni.2012.06.020
18. Mjosberg J, Bernink J, Golebski K, Karrich JJ, Peters CP, Blom B,
et al. The transcription factor GATA3 is essential for the function
of human Type 2 innate lymphoid cells. Immunity. (2012) 37:649–59.
doi: 10.1016/j.immuni.2012.08.015
19. Bernink JH, Peters CP, Munneke M, Te Velde AA, Meijer SL, Weijer K, et al.
Human type 1 innate lymphoid cells accumulate in inflamedmucosal tissues.
Nat Immunol. (2013) 14:221–9. doi: 10.1038/ni.2534
20. Fuchs A, Vermi W, Lee JS, Lonardi S, Gilfillan S, Newberry RD, et al.
Intraepithelial Type 1 innate lymphoid cells are a unique subset of IL-12- and
IL-15-responsive IFN-gamma-producing cells. Immunity. (2013) 38:769–81.
doi: 10.1016/j.immuni.2013.02.010
21. Klose CS, FlachM,Mohle L, Rogell L, Hoyler T, Ebert K, et al. Differentiation
of Type 1 ILCs from a common progenitor to all helper-like innate
lymphoid cell lineages. Cell. (2014) 157:340–56. doi: 10.1016/j.cell.2014.
03.030
22. Spits H, Artis D, ColonnaM, Diefenbach A, Di Santo JP, Eberl G, et al. Innate
lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol.
(2013) 13:145–9. doi: 10.1038/nri3365
23. Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G,
et al. Innate lymphoid cells: 10 years on. Cell. (2018) 174:1054–66.
doi: 10.1016/j.cell.2018.07.017
24. Diefenbach A, Colonna M, Koyasu S. Development, differentiation,
and diversity of innate lymphoid cells. Immunity. (2014) 41:354–65.
doi: 10.1016/j.immuni.2014.09.005
25. Cherrier DE, Serafini N, Di Santo JP. Innate lymphoid cell
development: a T cell perspective. Immunity. (2018) 48:1091–103.
doi: 10.1016/j.immuni.2018.05.010
26. Yang Q, Li F, Harly C, Xing S, Ye L, Xia X, et al. TCF-1 upregulation identifies
early innate lymphoid progenitors in the bone marrow.Nat Immunol. (2015)
16:1044–50. doi: 10.1038/ni.3248
27. Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge
A, et al. Systemic human ILC precursors provide a substrate
for tissue ILC differentiation. Cell. (2017) 168:1086–100 e1010.
doi: 10.1016/j.cell.2017.02.021
28. Yagi R, Zhong C, Northrup DL, Yu F, Bouladoux N, Spencer S, et al.
The transcription factor GATA3 is critical for the development of All IL-
7Ralpha-expressing innate lymphoid cells. Immunity. (2014) 40:378–88.
doi: 10.1016/j.immuni.2014.01.012
29. Peng H, Jiang X, Chen Y, Sojka DK, Wei H, Gao X, et al. Liver-resident NK
cells confer adaptive immunity in skin-contact inflammation. J Clin Invest.
(2013) 123:1444–56. doi: 10.1172/JCI66381
30. Gasteiger G, Fan X, Dikiy S, Lee SY, Rudensky AY. Tissue residency of
innate lymphoid cells in lymphoid and nonlymphoid organs. Science. (2015)
350:981–5. doi: 10.1126/science.aac9593
31. Moro K, Kabata H, Tanabe M, Koga S, Takeno N, Mochizuki M, et al.
Interferon and IL-27 antagonize the function of group 2 innate lymphoid
cells and type 2 innate immune responses. Nat Immunol. (2016) 17:76–86.
doi: 10.1038/ni.3309
32. Tanriver Y, Diefenbach A. Transcription factors controlling development
and function of innate lymphoid cells. Int Immunol. (2014) 26:119–28.
doi: 10.1093/intimm/dxt063
33. Townsend MJ, Weinmann AS, Matsuda JL, Salomon R, Farnham
PJ, Biron CA, et al. T-bet regulates the terminal maturation and
homeostasis of NK and Valpha14i NKT cells. Immunity. (2004) 20:477–94.
doi: 10.1016/S1074-7613(04)00076-7
34. Jenne CN, Enders A, Rivera R, Watson SR, Bankovich AJ, Pereira JP,
et al. T-bet-dependent S1P5 expression in NK cells promotes egress
from lymph nodes and bone marrow. J Exp Med. (2009) 206:2469–81.
doi: 10.1084/jem.20090525
35. Daussy C, Faure F, Mayol K, Viel S, Gasteiger G, Charrier E, et al. T-
bet and Eomes instruct the development of two distinct natural killer cell
lineages in the liver and in the bone marrow. J Exp Med. (2014) 211:563–77.
doi: 10.1084/jem.20131560
36. Sojka DK, Plougastel-Douglas B, Yang L, Pak-Wittel MA, Artyomov MN,
Ivanova Y, et al. Tissue-resident natural killer (NK) cells are cell lineages
distinct from thymic and conventional splenic NK cells. Elife. (2014)
3:e01659. doi: 10.7554/eLife.01659.015
37. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG,
Doering TA, et al. Innate lymphoid cells promote lung-tissue homeostasis
after infection with influenza virus. Nat Immunol. (2011) 12:1045–54.
doi: 10.1038/ni.2131
38. Wilhelm C, Hirota K, Stieglitz B, Van Snick J, Tolaini M, Lahl K, et al. An
IL-9 fate reporter demonstrates the induction of an innate IL-9 response in
lung inflammation. Nat Immunol. (2011) 12:1071–7. doi: 10.1038/ni.2133
39. Halim TY, Maclaren A, Romanish MT, Gold MJ, Mcnagny KM, Takei F.
Retinoic-acid-receptor-related orphan nuclear receptor alpha is required for
natural helper cell development and allergic inflammation. Immunity. (2012)
37:463–74. doi: 10.1016/j.immuni.2012.06.012
40. Wong SH, Walker JA, Jolin HE, Drynan LF, Hams E, Camelo A, et al.
Transcription factor RORalpha is critical for nuocyte development. Nat
Immunol. (2012) 13:229–36. doi: 10.1038/ni.2208
41. Walker JA, Oliphant CJ, Englezakis A, Yu Y, Clare S, Rodewald HR, et al.
Bcl11b is essential for group 2 innate lymphoid cell development. J Exp Med.
(2015) 212:875–82. doi: 10.1084/jem.20142224
42. Yu Y, Wang C, Clare S, Wang J, Lee SC, Brandt C, et al. The transcription
factor Bcl11b is specifically expressed in group 2 innate lymphoid cells
and is essential for their development. J Exp Med. (2015) 212:865–74.
doi: 10.1084/jem.20142318
43. Sawa S, Cherrier M, Lochner M, Satoh-Takayama N, Fehling HJ, Langa F,
et al. Lineage relationship analysis of RORgammat+ innate lymphoid cells.
Science. (2010) 330:665–9. doi: 10.1126/science.1194597
44. Klose CS, Kiss EA, Schwierzeck V, Ebert K, Hoyler T, D’hargues Y, et al. A
T-bet gradient controls the fate and function of CCR6-RORgammat+ innate
lymphoid cells. Nature. (2013) 494:261–5. doi: 10.1038/nature11813
45. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens
S, Flavell RA. Innate and adaptive interleukin-22 protects mice
from inflammatory bowel disease. Immunity. (2008) 29:947–57.
doi: 10.1016/j.immuni.2008.11.003
46. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-
22 mediates early host defense against attaching and effacing bacterial
pathogens. Nat Med. (2008) 14:282–9. doi: 10.1038/nm1720
47. Hanash AM, Dudakov JA, Hua G, O’connor MH, Young LF, Singer NV,
et al. Interleukin-22 protects intestinal stem cells from immune-mediated
tissue damage and regulates sensitivity to graft versus host disease. Immunity.
(2012) 37:339–50. doi: 10.1016/j.immuni.2012.05.028
48. Sonnenberg GF, Monticelli LA, Alenghat T, Fung TC, Hutnick NA,
Kunisawa J, et al. Innate lymphoid cells promote anatomical containment
of lymphoid-resident commensal bacteria. Science. (2012) 336:1321–5.
doi: 10.1126/science.1222551
49. Goto Y, Obata T, Kunisawa J, Sato S, Ivanov Ii, Lamichhane A, et al. Innate
lymphoid cells regulate intestinal epithelial cell glycosylation. Science. (2014)
345:1254009. doi: 10.1126/science.1254009
Frontiers in Immunology | www.frontiersin.org 17 July 2020 | Volume 11 | Article 813
Stokic-Trtica et al. NK and ILC Development
50. Hernandez PP, Mahlakoiv T, Yang I, Schwierzeck V, Nguyen N, Guendel
F, et al. Interferon-lambda and interleukin 22 act synergistically for the
induction of interferon-stimulated genes and control of rotavirus infection.
Nat Immunol. (2015) 16:698–707. doi: 10.1038/ni.3180
51. Gronke K, Hernandez PP, Zimmermann J, Klose CSN, Kofoed-Branzk
M, Guendel F, et al. Interleukin-22 protects intestinal stem cells against
genotoxic stress. Nature. (2019) 566:249–53. doi: 10.1038/s41586-019-
0899-7
52. Vonarbourg C, Mortha A, Bui VL, Hernandez PP, Kiss EA, Hoyler
T, et al. Regulated expression of nuclear receptor RORgammat
confers distinct functional fates to NK cell receptor-expressing
RORgammat(+) Innate Lymphocytes. Immunity. (2010) 33:736–51.
doi: 10.1016/j.immuni.2010.10.017
53. Sciume G, Hirahara K, Takahashi H, Laurence A, Villarino AV, Singleton KL,
et al. Distinct requirements for T-bet in gut innate lymphoid cells. J ExpMed.
(2012) 209:2331–8. doi: 10.1084/jem.20122097
54. Gladiator A, Wangler N, Trautwein-Weidner K, Leibundgut-Landmann
S. Cutting edge: IL-17-secreting innate lymphoid cells are essential for
host defense against fungal infection. J Immunol. (2013) 190:521–5.
doi: 10.4049/jimmunol.1202924
55. Rankin LC, Groom JR, Chopin M, Herold MJ, Walker JA, Mielke LA, et al.
The transcription factor T-bet is essential for the development of NKp46(+)
innate lymphocytes via the Notch pathway. Nat Immunol. (2013) 14:389–95.
doi: 10.1038/ni.2545
56. Constantinides MG, Gudjonson H, Mcdonald BD, Ishizuka IE, Verhoef
PA, Dinner AR, et al. PLZF expression maps the early stages of
ILC1 lineage development. Proc Natl Acad Sci USA. (2015) 112:5123–8.
doi: 10.1073/pnas.1423244112
57. Klose CS, Artis D. Innate lymphoid cells as regulators of immunity,
inflammation and tissue homeostasis. Nat Immunol. (2016) 17:765–74.
doi: 10.1038/ni.3489
58. Salimi M, Xue L, Jolin H, Hardman C, Cousins DJ, Mckenzie AN,
et al. Group 2 innate lymphoid cells express functional NKp30 receptor
inducing Type 2 cytokine production. J Immunol. (2016) 196:45–54.
doi: 10.4049/jimmunol.1501102
59. Spits H, Bernink JH, Lanier L. NK cells and type 1 innate lymphoid
cells: partners in host defense. Nat Immunol. (2016) 17:758–64.
doi: 10.1038/ni.3482
60. Medzhitov R, Janeway CAJr. Decoding the patterns of self and
nonself by the innate immune system. Science. (2002) 296:298–300.
doi: 10.1126/science.1068883
61. Diefenbach A, Raulet DH. Innate immune recognition by
stimulatory immunoreceptors. Curr Opin Immunol. (2003) 15:37–44.
doi: 10.1016/S0952-7915(02)00007-9
62. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic
cells prime natural killer cells by trans-presenting interleukin 15. Immunity.
(2007) 26:503–17. doi: 10.1016/j.immuni.2007.03.006
63. Kaifu T, Escaliere B, Gastinel LN, Vivier E, Baratin M. B7-H6/NKp30
interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life
Sci. (2011) 68:3531–9. doi: 10.1007/s00018-011-0802-7
64. Hammer Q, Ruckert T, Romagnani C. Natural killer cell specificity for viral
infections. Nat Immunol. (2018) 19:800–8. doi: 10.1038/s41590-018-0163-6
65. Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern
recognition: a cell biological perspective. Annu Rev Immunol. (2015) 33:257–
90. doi: 10.1146/annurev-immunol-032414-112240
66. Janeway CA Jr, Medzhitov R. Innate immune
recognition. Annu Rev Immunol. (2002) 20:197–216.
doi: 10.1146/annurev.immunol.20.083001.084359
67. Kishore U. Target pattern recognition in innate immunity.Adv ExpMed Biol.
(2009) 653:ix–x. doi: 10.1007/978-1-4419-0901-5
68. Podojil JR, Miller SD. Molecular mechanisms of T-cell receptor and
costimulatory molecule ligation/blockade in autoimmune disease therapy.
Immunol Rev. (2009) 229:337–55. doi: 10.1111/j.1600-065X.2009.00773.x
69. Hsieh C, Macatonia S, Tripp C, Wolf S, O’garra A, Murphy K. Development
of Th1 CD4+ T-cells through IL-12 produced by Listeria-induced
macrophages. Science. (1993) 260:547–9. doi: 10.1126/science.8097338
70. Duncan DD, Swain SL. Role of antigen-presenting cells in the
polarized development of helper T cell subsets: evidence for differential
cytokine production by Th0 cells in response to antigen presentation
by B cells and macrophages. Eur J Immunol. (1994) 24:2506–14.
doi: 10.1002/eji.1830241037
71. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal
developmental pathways for the generation of pathogenic effector TH17 and
regulatory T cells. Nature. (2006) 441:235–8. doi: 10.1038/nature04753
72. Sokol CL, Barton GM, Farr AG,Medzhitov R. Amechanism for the initiation
of allergen-induced T helper type 2 responses.Nat Immunol. (2008) 9:310–8.
doi: 10.1038/ni1558
73. Adib-Conquy M, Scott-Algara D, Cavaillon JM, Souza-Fonseca-Guimaraes
F. TLR-mediated activation of NK cells and their role in bacterial/viral
immune responses in mammals. Immunol Cell Biol. (2014) 92:256–62.
doi: 10.1038/icb.2013.99
74. Brown MG, Dokun AO, Heusel JW, Smith HR, Beckman DL,
Blattenberger EA, et al. Vital involvement of a natural killer cell
activation receptor in resistance to viral infection. Science. (2001) 292:934–7.
doi: 10.1126/science.1060042
75. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition
of cytomegalovirus by activating and inhibitory NK cell receptors. Science.
(2002) 296:1323–6. doi: 10.1126/science.1070884
76. Szomolanyi-Tsuda E, Liang X, Welsh RM, Kurt-Jones EA, Finberg RW.
Role for TLR2 in NK cell-mediated control of murine cytomegalovirus
in vivo. J Virol. (2006) 80:4286–91. doi: 10.1128/JVI.80.9.4286-429
1.2006
77. Hammer Q, Ruckert T, Borst EM, Dunst J, Haubner A, Durek P,
et al. Peptide-specific recognition of human cytomegalovirus strains
controls adaptive natural killer cells. Nat Immunol. (2018) 19:453–63.
doi: 10.1038/s41590-018-0082-6
78. Karre K. Natural killer cell recognition of missing self. Nat Immunol. (2008)
9:477–80. doi: 10.1038/ni0508-477
79. Ljunggren H-G, Karre K. Host resistance directed selectively against
H-2-deficient lymphoma variants. J Exp Med. (1985) 162:1745–59.
doi: 10.1084/jem.162.6.1745
80. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-
deficient lymphoma variants suggests alternative immune defense strategy.
Nature. (1986) 319:675–8. doi: 10.1038/319675a0
81. Croft NP, Smith SA, Pickering J, Sidney J, Peters B, Faridi P, et al. Most viral
peptides displayed by class I MHC on infected cells are immunogenic. Proc
Natl Acad Sci USA. (2019) 116:3112–7. doi: 10.1073/pnas.1815239116
82. Karlhofer FM, Ribaudo RK, Yokoyama WM. MHC class I alloantigen
specificity of Ly-49+ IL-2 activated natural killer cells.Nature. (1992) 358:66–
70. doi: 10.1038/358066a0
83. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members
associated with HLA-C andHLA-B recognition by human natural killer cells.
Science. (1995) 268:405–8. doi: 10.1126/science.7716543
84. Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO. Killer
cell inhibitory receptors specific for HLA-C and HLA-B identified by
direct binding and by functional transfer. Immunity. (1995) 3:801–9.
doi: 10.1016/1074-7613(95)90069-1
85. Braud VM, Allan DSJ, O’callaghan CA, Soderstrom K, D’andrea A, Ogg GS,
et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B, and C.
Nature. (1998) 391:795–9. doi: 10.1038/35869
86. Samaridis J, Colonna M. Cloning of novel immunoglobulin superfamily
receptors expressed on human myeloid and lymphoid cells: structural
evidence for new stimulatory and inhibitory pathways. Eur J Immunol.
(1997) 27:660–5. doi: 10.1002/eji.1830270313
87. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating
and inhibitory receptors of natural killer cells. Immunol Cell Biol. (2011)
89:216–24. doi: 10.1038/icb.2010.78
88. Ohlen C, Kling G, Hoglund P, Hansson M, Scangos G, Bieberich C,
et al. Prevention of allogeneic bone marrow graft rejection of H-2
transgene in donor mice. Science. (1989) 246:666–8. doi: 10.1126/science.28
14488
89. BixM, Liao N-S, ZijlstraM, Loring J, Jaenisch R, Raulet D. Rejection of class I
MHC-deficient hemopoietic cells by irradiated MHC-matched mice.Nature.
(1991) 349:329–31. doi: 10.1038/349329a0
90. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev
Immunol. (2003) 3:781–90. doi: 10.1038/nri1199
Frontiers in Immunology | www.frontiersin.org 18 July 2020 | Volume 11 | Article 813
Stokic-Trtica et al. NK and ILC Development
91. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation
of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Science. (1999) 285:727–9. doi: 10.1126/science.285.5428.727
92. Cerwenka A, Bakker ABH, Mcclanahan T, Wagner J, Wu J, Phillips
JH, et al. Retinoic acid early inducible genes define a ligand family
for the activating NKG2D receptor in mice. Immunity. (2000) 12:721–7.
doi: 10.1016/S1074-7613(00)80222-8
93. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the
murine NKG2D receptor: expression by tumor cells and activation of NK
cells and macrophages. Nat Immunol. (2000) 1:119–26. doi: 10.1038/77793
94. Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow
W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV
glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D
receptor. Immunity. (2001) 14:123–33. doi: 10.1016/S1074-7613(01)0
0095-4
95. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair
expression of NKG2D and T- cell activation. Nature. (2002) 419:734–8.
doi: 10.1038/nature01112
96. Takada A, Yoshida S, KajikawaM,Miyatake Y, Tomaru U, SakaiM, et al. Two
Novel NKG2D ligands of the mouse H60 family with differential expression
patterns and binding affinities to NKG2D. J Immunol. (2008) 180:1678–85.
doi: 10.4049/jimmunol.180.3.1678
97. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, et al. The B7
family member B7-H6 is a tumor cell ligand for the activating natural
killer cell receptor NKp30 in humans. J Exp Med. (2009) 206:1495–503.
doi: 10.1084/jem.20090681
98. Constantinides MG, Mcdonald BD, Verhoef PA, Bendelac A. A committed
precursor to innate lymphoid cells. Nature. (2014) 508:397–401.
doi: 10.1038/nature13047
99. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common
lymphoid progenitors in mouse bone marrow. Cell. (1997) 91:661–72.
doi: 10.1016/S0092-8674(00)80453-5
100. Klose CS, Diefenbach A. Transcription factors controlling innate lymphoid
cell fate decisions. Curr Top Microbiol Immunol. (2014) 381:215–55.
doi: 10.1007/82_2014_381
101. Zook EC, Kee BL. Development of innate lymphoid cells. Nat Immunol.
(2016) 17:775–82. doi: 10.1038/ni.3481
102. Sitnicka E, Bryder D, Theilgaard-Monch K, Buza-Vidas N, Adolfsson J,
Jacobsen SE. Key role of flt3 ligand in regulation of the common lymphoid
progenitor but not in maintenance of the hematopoietic stem cell pool.
Immunity. (2002) 17:463–72. doi: 10.1016/S1074-7613(02)00419-3
103. Possot C, Schmutz S, Chea S, Boucontet L, Louise A, Cumano A, et al.
Notch signaling is necessary for adult, but not fetal, development of
RORgammat(+) innate lymphoid cells. Nat Immunol. (2011) 12:949–58.
doi: 10.1038/ni.2105
104. Yu X, Wang Y, Deng M, Li Y, Ruhn KA, Zhang CC, et al. The
basic leucine zipper transcription factor NFIL3 directs the development
of a common innate lymphoid cell precursor. Elife. (2014) 3:e04406.
doi: 10.7554/eLife.04406.017
105. Yokota Y, Mansouri A, Mori S, Sugawara S, Adachi S, Nishikawa S,
et al. Development of peripheral lymphoid organs and natural killer cells
depends on the helix-loop-helix inhibitor Id2. Nature. (1999) 397:702–6.
doi: 10.1038/17812
106. Harly C, Cam M, Kaye J, Bhandoola A. Development and differentiation
of early innate lymphoid progenitors. J Exp Med. (2018) 215:249–62.
doi: 10.1084/jem.20170832
107. Sanos SL, Diefenbach A. Innate lymphoid cells: from border protection to
the initiation of inflammatory diseases. Immunol Cell Biol. (2013) 91:215–24.
doi: 10.1038/icb.2013.3
108. Murre C. Helix-loop-helix proteins and lymphocyte development. Nat
Immunol. (2005) 6:1079–86. doi: 10.1038/ni1260
109. BoosMD, Yokota Y, Eberl G, Kee BL.Mature natural killer cell and lymphoid
tissue-inducing cell development requires Id2-mediated suppression of
E protein activity. J Exp Med. (2007) 204:1119–30. doi: 10.1084/jem.20
061959
110. Rawlins EL, Clark CP, Xue Y, Hogan BL. The Id2+ distal tip lung epithelium
contains individual multipotent embryonic progenitor cells. Development.
(2009) 136:3741–5. doi: 10.1242/dev.037317
111. Walker JA, Clark PA, Crisp A, Barlow JL, Szeto A, Ferreira ACF, et al.
Polychromic reporter mice reveal unappreciated innate lymphoid cell
progenitor heterogeneity and elusive ILC3 progenitors in bone marrow.
Immunity. (2019) 51:104–18 e107. doi: 10.1016/j.immuni.2019.05.002
112. Xu W, Cherrier DE, Chea S, Vosshenrich C, Serafini N, Petit
M, et al. An Id2(RFP)-reporter mouse redefines innate lymphoid
cell precursor potentials. Immunity. (2019) 50:1054–68 e1053.
doi: 10.1016/j.immuni.2019.02.022
113. Ishizuka IE, Chea S, Gudjonson H, Constantinides MG, Dinner AR,
Bendelac A, et al. Single-cell analysis defines the divergence between the
innate lymphoid cell lineage and lymphoid tissue-inducer cell lineage. Nat
Immunol. (2016) 17:269–76. doi: 10.1038/ni.3344
114. Zhong C, Zheng M, Cui K, Martins AJ, Hu G, Li D, et al. Differential
expression of the transcription factor GATA3 specifies lineage and
functions of innate lymphoid cells. Immunity. (2020) 52:83–95 e84.
doi: 10.1016/j.immuni.2019.12.001
115. Yu Y, Tsang JC, Wang C, Clare S, Wang J, Chen X, et al. Single-cell RNA-seq
identifies a PD-1(hi) ILC progenitor and defines its development pathway.
Nature. (2016) 539:102–6. doi: 10.1038/nature20105
116. Harly C, Kenney D, Ren G, Lai B, Raabe T, Yang Q, et al. The transcription
factor TCF-1 enforces commitment to the innate lymphoid cell lineage. Nat
Immunol. (2019) 20:1150–60. doi: 10.1038/s41590-019-0445-7
117. Gascoyne DM, Long E, Veiga-Fernandes H, De Boer J, Williams O, Seddon
B, et al. The basic leucine zipper transcription factor E4BP4 is essential
for natural killer cell development. Nat Immunol. (2009) 10:1118–24.
doi: 10.1038/ni.1787
118. Kamizono S, Duncan GS, Seidel MG, Morimoto A, Hamada K, Grosveld
G, et al. Nfil3/E4bp4 is required for the development and maturation of
NK cells in vivo. J Exp Med. (2009) 206:2977–86. doi: 10.1084/jem.20
092176
119. FirthMA,Madera S, Beaulieu AM, Gasteiger G, Castillo EF, Schluns KS, et al.
Nfil3-independent lineage maintenance and antiviral response of natural
killer cells. J Exp Med. (2013) 210:2981–90. doi: 10.1084/jem.20130417
120. Geiger TL, Abt MC, Gasteiger G, Firth MA, O’connor MH, Geary CD,
et al. Nfil3 is crucial for development of innate lymphoid cells and host
protection against intestinal pathogens. J Exp Med. (2014) 211:1723–31.
doi: 10.1084/jem.20140212
121. Seillet C, Rankin LC, Groom JR, Mielke LA, Tellier J, ChopinM, et al. Nfil3 is
required for the development of all innate lymphoid cell subsets. J Exp Med.
(2014) 211:1733–40. doi: 10.1084/jem.20140145
122. Xu W, Domingues RG, Fonseca-Pereira D, Ferreira M, Ribeiro H,
Lopez-Lastra S, et al. NFIL3 orchestrates the emergence of common
helper innate lymphoid cell precursors. Cell Rep. (2015) 10:2043–54.
doi: 10.1016/j.celrep.2015.02.057
123. Aliahmad P, De La Torre B, Kaye J. Shared dependence on the DNA-
binding factor TOX for the development of lymphoid tissue-inducer cell
and NK cell lineages. Nat Immunol. (2010) 11:945–52. doi: 10.1038/ni.
1930
124. Seehus CR, Aliahmad P, De La Torre B, Iliev ID, Spurka L, Funari VA,
et al. The development of innate lymphoid cells requires TOX-dependent
generation of a common innate lymphoid cell progenitor. Nat Immunol.
(2015) 16:599–608. doi: 10.1038/ni.3168
125. Zhu J. GATA3 Regulates the development and functions of innate
lymphoid cell subsets at multiple stages. Front Immunol. (2017) 8:1571.
doi: 10.3389/fimmu.2017.01571
126. Samson SI, Richard O, Tavian M, Ranson T, Vosshenrich CA, Colucci
F, et al. GATA-3 promotes maturation, IFN-gamma production,
and liver-specific homing of NK cells. Immunity. (2003) 19:701–11.
doi: 10.1016/S1074-7613(03)00294-2
127. Bando JK, Liang HE, Locksley RM. Identification and distribution of
developing innate lymphoid cells in the fetal mouse intestine. Nat Immunol.
(2015) 16:153–60. doi: 10.1038/ni.3057
128. Schneider C, Lee J, Koga S, Ricardo-Gonzalez RR, Nussbaum JC, Smith LK,
et al. Tissue-resident group 2 innate lymphoid cells differentiate by layered
ontogeny and in situ perinatal priming. Immunity. (2019) 50:1425–38 e1425.
doi: 10.1016/j.immuni.2019.04.019
129. Rosmaraki EE, Douagi I, Roth C, Colucci F, Cumano
A, Di Santo JP. Identification of committed NK cell
Frontiers in Immunology | www.frontiersin.org 19 July 2020 | Volume 11 | Article 813
Stokic-Trtica et al. NK and ILC Development
progenitors in adult murine bone marrow. Eur J Immunol.
(2001) 31:1900–9. doi: 10.1002/1521-4141(200106)31:6<1900::
aid-immu1900>3.0.co;2-m
130. Matsuda JL, George TC, Hagman J, Gapin L. Temporal
dissection of T-bet functions. J Immunol. (2007) 178:3457–65.
doi: 10.4049/jimmunol.178.6.3457
131. Nozad Charoudeh H, Tang Y, Cheng M, Cilio CM, Jacobsen SE, Sitnicka E.
Identification of an NK/T cell-restricted progenitor in adult bone marrow
contributing to bonemarrow- and thymic-dependent NK cells. Blood. (2010)
116:183–92. doi: 10.1182/blood-2009-10-247130
132. Fathman JW, Bhattacharya D, Inlay MA, Seita J, Karsunky H,
Weissman IL. Identification of the earliest natural killer cell-committed
progenitor in murine bone marrow. Blood. (2011) 118:5439–47.
doi: 10.1182/blood-2011-04-348912
133. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S,
et al. IL-15 receptor maintains lymphoid homeostasis by supporting
lymphocyte homing and proliferation. Immunity. (1998) 9:669–76.
doi: 10.1016/S1074-7613(00)80664-0
134. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers
M, et al. Reversible defects in natural killer and memory CD8T cell
lineages in interleukin 15-deficient mice. J Exp Med. (2000) 191:771–80.
doi: 10.1084/jem.191.5.771
135. Koka R, Burkett PR, Chien M, Chai S, Chan F, Lodolce JP, et al.
Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal
but not IL-15R[alpha]-deficient mice. J Exp Med. (2003) 197:977–84.
doi: 10.1084/jem.20021836
136. Kim S, Iizuka K, Kang HS, Dokun A, French AR, Greco S, et al. In vivo
developmental stages in murine natural killer cell maturation. Nat Immunol.
(2002) 3:523–8. doi: 10.1038/ni796
137. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental
pathways that generate natural-killer-cell diversity in mice and
humans. Nat Rev Immunol. (2007) 7:703–14. doi: 10.1038/n
ri2154
138. Narni-Mancinelli E, Chaix J, Fenis A, Kerdiles YM, Yessaad N, Reynders
A, et al. Fate mapping analysis of lymphoid cells expressing the NKp46
cell surface receptor. Proc Natl Acad Sci USA. (2011) 108:18324–9.
doi: 10.1073/pnas.1112064108
139. Goh W, Huntington ND. Regulation of murine natural killer cell
development. Front Immunol. (2017) 8:130. doi: 10.3389/fimmu.2017.
00130
140. Vosshenrich CA, Di Santo JP. Developmental programming of natural
killer and innate lymphoid cells. Curr Opin Immunol. (2013) 25:130–8.
doi: 10.1016/j.coi.2013.02.002
141. Fuchs A. ILC1s in Tissue inflammation and infection. Front Immunol. (2016)
7:104. doi: 10.3389/fimmu.2016.00104
142. Takeda K, Cretney E, Hayakawa Y, Ota T, Akiba H, Ogasawara K, et al.
TRAIL identifies immature natural killer cells in newborn mice and
adult mouse liver. Blood. (2005) 105:2082–9. doi: 10.1182/blood-2004-0
8-3262
143. Huntington ND, Tabarias H, Fairfax K, Brady J, Hayakawa Y, Degli-
Esposti MA, et al. NK cell maturation and peripheral homeostasis is
associated with KLRG1 up-regulation. J Immunol. (2007) 178:4764–70.
doi: 10.4049/jimmunol.178.8.4764
144. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets
with distinct responsiveness and migratory capacity. J Immunol. (2006)
176:1517–24. doi: 10.4049/jimmunol.176.3.1517
145. Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer
T. Maturation of mouse NK cells is a 4-stage developmental
program. Blood. (2009) 113:5488–96. doi: 10.1182/blood-2008-10-
187179
146. Vosshenrich CA, Ranson T, Samson SI, Corcuff E, Colucci F, Rosmaraki
EE, et al. Roles for common cytokine receptor gamma-chain-dependent
cytokines in the generation, differentiation, and maturation of NK cell
precursors and peripheral NK cells in vivo. J Immunol. (2005) 174:1213–21.
doi: 10.4049/jimmunol.174.3.1213
147. Ranson T, Vosshenrich CA, Corcuff E, Richard O,MullerW, Di Santo JP. IL-
15 is an essential mediator of peripheral NK-cell homeostasis. Blood. (2003)
101:4887–93. doi: 10.1182/blood-2002-11-3392
148. Klose CSN, Blatz K, D’hargues Y, Hernandez PP, Kofoed-Nielsen M,
Ripka JF, et al. The transcription factor T-bet is induced by IL-
15 and thymic agonist selection and controls CD8 alpha alpha(+)
intraepithelial lymphocyte development. Immunity. (2014) 41:230–43.
doi: 10.1016/j.immuni.2014.06.018
149. Reis BS, Hoytema Van Konijnenburg DP, Grivennikov SI,
Mucida D. Transcription factor T-bet regulates intraepithelial
lymphocyte functional maturation. Immunity. (2014) 41:244–56.
doi: 10.1016/j.immuni.2014.06.017
150. Fan X, Rudensky AY. Hallmarks of tissue-resident lymphocytes. Cell. (2016)
164:1198–211. doi: 10.1016/j.cell.2016.02.048
151. Ruscher R, Kummer RL, Lee YJ, Jameson SC, Hogquist KA. CD8alphaalpha
intraepithelial lymphocytes arise from two main thymic precursors. Nat
Immunol. (2017) 18:771–9. doi: 10.1038/ni.3751
152. Klose CSN, Hummel JF, Faller L, D’hargues Y, Ebert K, Tanriver Y.
A committed postselection precursor to natural TCRalphabeta(+)
intraepithelial lymphocytes. Mucosal Immunol. (2018) 11:333–44.
doi: 10.1038/mi.2017.54
153. Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T,
et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5
for NK-cell survival and development. Blood. (2011) 117:1565–73.
doi: 10.1182/blood-2010-06-291633
154. Huntington ND, Puthalakath H, Gunn P, Naik E, Michalak EM, Smyth MJ,
et al. Interleukin 15-mediated survival of natural killer cells is determined by
interactions among Bim, Noxa and Mcl-1. Nat Immunol. (2007) 8:856–63.
doi: 10.1038/ni1487
155. Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S, et al. The
Ikaros gene is required for the development of all lymphoid lineages. Cell.
(1994) 79:143–56. doi: 10.1016/0092-8674(94)90407-3
156. Colucci F, Samson SI, Dekoter RP, Lantz O, Singh H, Di Santo JP.
Differential requirement for the transcription factor PU.1 in the generation
of natural killer cells versus B and T cells. Blood. (2001) 97:2625–32.
doi: 10.1182/blood.V97.9.2625
157. Nutt SL, Metcalf D, D’amico A, Polli M, Wu L. Dynamic regulation of PU.1
expression in multipotent hematopoietic progenitors. J Exp Med. (2005)
201:221–31. doi: 10.1084/jem.20041535
158. Yoshida T, Ng SY, Zuniga-Pflucker JC, Georgopoulos K. Early hematopoietic
lineage restrictions directed by Ikaros. Nat Immunol. (2006) 7:382–91.
doi: 10.1038/ni1314
159. Huntington ND, Nutt SL, Carotta S. Regulation of murine natural killer cell
commitment. Front Immunol. (2013) 4:14. doi: 10.3389/fimmu.2013.00014
160. Held W, Kunz B, Lowin-Kropf B, Van De Wetering M, Clevers
H. Clonal acquisition of the Ly49A NK cell receptor is dependent
on the trans-acting factor TCF-1. Immunity. (1999) 11:433–42.
doi: 10.1016/S1074-7613(00)80118-1
161. Jeevan-Raj B, Gehrig J, Charmoy M, Chennupati V, Grandclement C,
Angelino P, et al. The transcription factor Tcf1 contributes to normal NK
cell development and function by limiting the expression of granzymes. Cell
Rep. (2017) 20:613–26. doi: 10.1016/j.celrep.2017.06.071
162. Seillet C, Huntington ND, Gangatirkar P, Axelsson E, Minnich M, Brady
HJ, et al. Differential requirement for Nfil3 during NK cell development. J
Immunol. (2014) 192:2667–76. doi: 10.4049/jimmunol.1302605
163. Male V, Nisoli I, Kostrzewski T, Allan DS, Carlyle JR, Lord GM, et al. The
transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and
directly regulates Eomes and Id2 expression. J Exp Med. (2014) 211:635–42.
doi: 10.1084/jem.20132398
164. Barton K, Muthusamy N, Fischer C, Ting CN, Walunas TL,
Lanier LL, et al. The Ets-1 transcription factor is required for the
development of natural killer cells in mice. Immunity. (1998) 9:555–63.
doi: 10.1016/S1074-7613(00)80638-X
165. Ramirez K, Chandler KJ, Spaulding C, Zandi S, Sigvardsson M, Graves
BJ, et al. Gene deregulation and chronic activation in natural killer cells
deficient in the transcription factor ETS1. Immunity. (2012) 36:921–32.
doi: 10.1016/j.immuni.2012.04.006
166. Zook EC, Ramirez K, Guo X, Van Der Voort G, Sigvardsson M, Svensson
EC, et al. The ETS1 transcription factor is required for the development
and cytokine-induced expansion of ILC2. J Exp Med. (2016) 213:687–96.
doi: 10.1084/jem.20150851
Frontiers in Immunology | www.frontiersin.org 20 July 2020 | Volume 11 | Article 813
Stokic-Trtica et al. NK and ILC Development
167. Lacorazza HD, Miyazaki Y, Di Cristofano A, Deblasio A, Hedvat C, Zhang J,
et al. The ETS protein MEF plays a critical role in perforin gene expression
and the development of natural killer and NK-T cells. Immunity. (2002)
17:437–49. doi: 10.1016/S1074-7613(02)00422-3
168. Vosshenrich CA, Garcia-Ojeda ME, Samson-Villeger SI, Pasqualetto V,
Enault L, Richard-Le Goff O, et al. A thymic pathway of mouse natural killer
cell development characterized by expression of GATA-3 and CD127. Nat
Immunol. (2006) 7:1217–24. doi: 10.1038/ni1395
169. Ali AK, Oh JS, Vivier E, Busslinger M, Lee SH. NK cell-specific
Gata3 ablation identifies the maturation program required for bone
marrow exit and control of proliferation. J Immunol. (2016) 196:1753–67.
doi: 10.4049/jimmunol.1501593
170. Delconte RB, Shi W, Sathe P, Ushiki T, Seillet C, Minnich M,
et al. The helix-loop-helix protein ID2 governs NK cell fate by
tuning their sensitivity to Interleukin-15. Immunity. (2016) 44:103–15.
doi: 10.1016/j.immuni.2015.12.007
171. Zook EC, Li ZY, Xu Y, De Pooter RF, Verykokakis M, Beaulieu A, et al.
Transcription factor ID2 prevents E proteins from enforcing a naive T
lymphocyte gene program during NK cell development. Sci Immunol. (2018)
3:aao2139. doi: 10.1126/sciimmunol.aao2139
172. Sathe P, Delconte RB, Souza-Fonseca-Guimaraes F, Seillet C, Chopin
M, Vandenberg CJ, et al. Innate immunodeficiency following genetic
ablation of Mcl1 in natural killer cells. Nat Commun. (2014) 5:4539.
doi: 10.1038/ncomms5539
173. Robbins SH, Tessmer MS, Van Kaer L, Brossay L. Direct effects of T-bet and
MHC class I expression, but not STAT1, on peripheral NK cell maturation.
Eur J Immunol. (2005) 35:757–65. doi: 10.1002/eji.200425797
174. Soderquest K, Powell N, Luci C, Van Rooijen N, Hidalgo A, Geissmann
F, et al. Monocytes control natural killer cell differentiation to effector
phenotypes. Blood. (2011) 117:4511–8. doi: 10.1182/blood-2010-10-3
12264
175. Van HeldenMJ, Goossens S, Daussy C, Mathieu AL, Faure F, Marcais A, et al.
Terminal NK cell maturation is controlled by concerted actions of T-bet and
Zeb2 and is essential formelanoma rejection. J ExpMed. (2015) 212:2015–25.
doi: 10.1084/jem.20150809
176. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP,
et al. Control of effector CD8+ T cell function by the transcription factor
Eomesodermin. Science. (2003) 302:1041–3. doi: 10.1126/science.1090148
177. Banerjee A, Gordon SM, Intlekofer AM, Paley MA, Mooney EC, Lindsten T,
et al. Cutting edge: the transcription factor eomesodermin enables CD8+ T
cells to compete for the memory cell niche. J Immunol. (2010) 185:4988–92.
doi: 10.4049/jimmunol.1002042
178. Pikovskaya O, Chaix J, Rothman NJ, Collins A, Chen YH, Scipioni AM, et al.
Cutting edge: eomesodermin is sufficient to direct type 1 innate lymphocyte
development into the conventional NK lineage. J Immunol. (2016) 196:1449–
54. doi: 10.4049/jimmunol.1502396
179. Kwong B, Rua R, Gao Y, Flickinger JJr, Wang Y, Kruhlak MJ, et al.
T-bet-dependent NKp46+ innate lymphoid cells regulate the onset of
TH17-induced neuroinflammation. Nat Immunol. (2017) 18:1117–27.
doi: 10.1038/ni.3816
180. Shih HY, Sciume G, Mikami Y, Guo L, Sun HW, Brooks SR, et al.
Developmental acquisition of regulomes underlies innate lymphoid cell
functionality. Cell. (2016) 165:1120–33. doi: 10.1016/j.cell.2016.04.029
181. Cortez VS, Ulland TK, Cervantes-Barragan L, Bando JK, Robinette ML,
Wang Q, et al. SMAD4 impedes the conversion of NK cells into ILC1-like
cells by curtailing non-canonical TGF-beta signaling. Nat Immunol. (2017)
18:995–1003. doi: 10.1038/ni.3809
182. Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, et al.
Tumor immunoevasion by the conversion of effector NK cells into type 1
innate lymphoid cells.Nat Immunol. (2017) 18:1004–15. doi: 10.1038/ni.3800
183. Kallies A, Carotta S, Huntington ND, Bernard NJ, Tarlinton DM,
Smyth MJ, et al. A role for Blimp1 in the transcriptional network
controlling natural killer cell maturation. Blood. (2011) 117:1869–79.
doi: 10.1182/blood-2010-08-303123
184. HolmesML,HuntingtonND, Thong RP, Brady J, Hayakawa Y, Andoniou CE,
et al. Peripheral natural killer cell maturation depends on the transcription
factor Aiolos. EMBO J. (2014) 33:2721–34. doi: 10.15252/embj.201487900
185. Rabacal W, Pabbisetty SK, Hoek KL, Cendron D, Guo Y, Maseda
D, et al. Transcription factor KLF2 regulates homeostatic NK cell
proliferation and survival. Proc Natl Acad Sci USA. (2016) 113:5370–5.
doi: 10.1073/pnas.1521491113
186. Lohoff M, Duncan GS, Ferrick D, Mittrucker HW, Bischof S, Prechtl S, et al.
Deficiency in the transcription factor interferon regulatory factor (IRF)-2
leads to severely compromised development of natural killer and T helper
type 1 cells. J Exp Med. (2000) 192:325–36. doi: 10.1084/jem.192.3.325
187. Taki S, Nakajima S, Ichikawa E, Saito T, Hida S. IFN regulatory
factor-2 deficiency revealed a novel checkpoint critical for the
generation of peripheral NK cells. J Immunol. (2005) 174:6005–12.
doi: 10.4049/jimmunol.174.10.6005
188. Wang S, Xia P, Huang G, Zhu P, Liu J, Ye B, et al. FoxO1-mediated autophagy
is required for NK cell development and innate immunity. Nat Commun.
(2016) 7:11023. doi: 10.1038/ncomms11023
189. Deng Y, Kerdiles Y, Chu J, Yuan S, Wang Y, Chen X, et al. Transcription
factor Foxo1 is a negative regulator of natural killer cell maturation
and function. Immunity. (2015) 42:457–70. doi: 10.1016/j.immuni.2015.
02.006
190. Huang P, Wang F, Yang Y, Lai W, Meng M, Wu S, et al. Hematopoietic-
specific deletion of Foxo1 promotes NK cell specification and proliferation.
Front Immunol. (2019) 10:1016. doi: 10.3389/fimmu.2019.01016
191. Cohen MM Jr. Perspectives on RUNX genes: an update. Am J Med Genet A.
(2009) 149:2629–46. doi: 10.1002/ajmg.a.33021
192. Ebihara T, Song C, Ryu SH, Plougastel-Douglas B, Yang L, Levanon D, et al.
Runx3 specifies lineage commitment of innate lymphoid cells.Nat Immunol.
(2015) 16:1124–33. doi: 10.1038/ni.3272
193. Tachibana M, Tenno M, Tezuka C, Sugiyama M, Yoshida H, Taniuchi I.
Runx1/Cbfbeta2 complexes are required for lymphoid tissue inducer cell
differentiation at two developmental stages. J Immunol. (2011) 186:1450–7.
doi: 10.4049/jimmunol.1000162
194. Miyamoto C, Kojo S, Yamashita M, Moro K, Lacaud G, Shiroguchi K,
et al. Runx/Cbfbeta complexes protect group 2 innate lymphoid cells from
exhausted-like hyporesponsiveness during allergic airway inflammation.Nat
Commun. (2019) 10:447. doi: 10.1038/s41467-019-08365-0
195. Guo Y, Maillard I, Chakraborti S, Rothenberg EV, Speck NA. Core binding
factors are necessary for natural killer cell development and cooperate
with Notch signaling during T-cell specification. Blood. (2008) 112:480–92.
doi: 10.1182/blood-2007-10-120261
196. Ohno S, Sato T, Kohu K, Takeda K, Okumura K, Satake M, et al. Runx
proteins are involved in regulation of CD122, Ly49 family and IFN-gamma
expression during NK cell differentiation. Int Immunol. (2008) 20:71–9.
doi: 10.1093/intimm/dxm120
197. Levanon D, Negreanu V, Lotem J, Bone KR, Brenner O, Leshkowitz D, et al.
Transcription factor Runx3 regulates interleukin-15-dependent natural killer
cell activation.Mol Cell Biol. (2014) 34:1158–69. doi: 10.1128/MCB.01202-13
198. Rapp M, Lau CM, Adams NM, Weizman OE, O’sullivan TE, Geary CD,
et al. Core-binding factor beta and Runx transcription factors promote
adaptive natural killer cell responses. Sci Immunol. (2017) 2:aan3796.
doi: 10.1126/sciimmunol.aan3796
199. Cortez VS, Cervantes-Barragan L, Robinette ML, Bando JK, Wang Y,
Geiger TL, et al. Transforming growth factor-beta signaling guides the
differentiation of innate lymphoid cells in salivary glands. Immunity. (2016)
44:1127–39. doi: 10.1016/j.immuni.2016.03.007
200. O’sullivan TE, Rapp M, Fan X, Weizman OE, Bhardwaj P, Adams
NM, et al. Adipose-resident group 1 innate lymphoid cells promote
obesity-associated insulin resistance. Immunity. (2016) 45:428–41.
doi: 10.1016/j.immuni.2016.06.016
201. Doisne JM, Balmas E, Boulenouar S, Gaynor LM, Kieckbusch J, Gardner L,
et al. Composition, development, and function of uterine innate lymphoid
cells. J Immunol. (2015) 195:3937–45. doi: 10.4049/jimmunol.1500689
202. Gabrielli S, Sun M, Bell A, Zook EC, De Pooter RF, Zamai L, et al. Murine
thymic NK cells are distinct from ILC1s and have unique transcription factor
requirements. Eur J Immunol. (2017) 47:800–5. doi: 10.1002/eji.201646871
203. Marotel M, Hasan U, Viel S, Marcais A, Walzer T. Back to the drawing
board: understanding the complexity of hepatic innate lymphoid cells. Eur
J Immunol. (2016) 46:2095–8. doi: 10.1002/eji.201646584
Frontiers in Immunology | www.frontiersin.org 21 July 2020 | Volume 11 | Article 813
Stokic-Trtica et al. NK and ILC Development
204. Cheng M, Charoudeh HN, Brodin P, Tang Y, Lakshmikanth T, Hoglund P,
et al. Distinct and overlapping patterns of cytokine regulation of thymic and
bone marrow-derived NK cell development. J Immunol. (2009) 182:1460–8.
doi: 10.4049/jimmunol.182.3.1460
205. Stewart CA, Walzer T, Robbins SH, Malissen B, Vivier E, Prinz I. Germ-
line and rearranged Tcrd transcription distinguish bona fide NK cells
and NK-like gammadelta T cells. Eur J Immunol. (2007) 37:1442–52.
doi: 10.1002/eji.200737354
206. Rodewald HR, Moingeon P, Lucich JL, Dosiou C, Lopez P, Reinherz EL. A
population of early fetal thymocytes expressing Fc gamma RII/III contains
precursors of T lymphocytes and natural killer cells. Cell. (1992) 69:139–50.
doi: 10.1016/0092-8674(92)90125-V
207. Buonocore S, Ahern PP, Uhlig HH, Ivanov Ii, Littman DR, Maloy KJ,
et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal
pathology. Nature. (2010) 464:1371–5. doi: 10.1038/nature08949
208. Peters CP, Mjosberg JM, Bernink JH, Spits H. Innate lymphoid cells
in inflammatory bowel diseases. Immunol Lett. (2016) 172:124–31.
doi: 10.1016/j.imlet.2015.10.004
209. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S,
et al. Identification and purification of natural killer cell stimulatory
factor (NKSF), a cytokine with multiple biologic effects on human
lymphocytes. J Exp Med. (1989) 170:827–45. doi: 10.1084/jem.170.
3.827
210. Weizman OE, Adams NM, Schuster IS, Krishna C, Pritykin Y, Lau C, et al.
ILC1 confer early host protection at initial sites of viral infection. Cell. (2017)
171:795–808 e712. doi: 10.1016/j.cell.2017.09.052
211. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, et al.
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired
in perforin-deficient mice. Nature. (1994) 369:31–7. doi: 10.1038/369031a0
212. Abt MC, Lewis BB, Caballero S, Xiong H, Carter RA, Susac B, et al. Innate
immune defenses mediated by two ILC subsets are critical for protection
against acute Clostridium difficile infection. Cell Host Microbe. (2015) 18:27–
37. doi: 10.1016/j.chom.2015.06.011
213. Mackay LK, Minnich M, Kragten NA, Liao Y, Nota B, Seillet C, et al. Hobit
and Blimp1 instruct a universal transcriptional program of tissue residency
in lymphocytes. Science. (2016) 352:459–63. doi: 10.1126/science.aa
d2035
214. Almeida FF, Tognarelli S, Marcais A, Kueh AJ, Friede ME, Liao Y, et al.
A point mutation in the Ncr1 signal peptide impairs the development
of innate lymphoid cell subsets. Oncoimmunology. (2018) 7:e1475875.
doi: 10.1080/2162402X.2018.1475875
215. Sheppard S, Schuster IS, Andoniou CE, Cocita C, Adejumo T, Kung SKP,
et al. The murine natural cytotoxic receptor NKp46/NCR1 Controls TRAIL
protein expression in NK cells and ILC1s. Cell Rep. (2018) 22:3385–92.
doi: 10.1016/j.celrep.2018.03.023
216. Turchinovich G, Ganter S, Barenwaldt A, Finke D. NKp46 calibrates
tumoricidal potential of Type 1 innate lymphocytes by regulating TRAIL
expression. J Immunol. (2018) 200:3762–8. doi: 10.4049/jimmunol.17
01333
217. Weizman OE, Song E, Adams NM, Hildreth AD, Riggan L, Krishna C,
et al. Mouse cytomegalovirus-experienced ILC1s acquire a memory response
dependent on the viral glycoprotein m12. Nat Immunol. (2019) 20:1004–11.
doi: 10.1038/s41590-019-0430-1
218. Paust S, Gill HS,Wang BZ, FlynnMP,Moseman EA, Senman B, et al. Critical
role for the chemokine receptor CXCR6 in NK cell-mediated antigen-
specific memory of haptens and viruses. Nat Immunol. (2010) 11:1127–35.
doi: 10.1038/ni.1953
219. Nandakumar V, Chou Y, Zang L, Huang XF, Chen SY. Epigenetic control of
natural killer cell maturation by histone H2A deubiquitinase, MYSM1. Proc
Natl Acad Sci U S A. (2013) 110:E3927–36. doi: 10.1073/pnas.1308888110
220. Yin J, Leavenworth JW, Li Y, Luo Q, Xie H, Liu X, et al. Ezh2
regulates differentiation and function of natural killer cells through histone
methyltransferase activity. Proc Natl Acad Sci U S A. (2015) 112:15988–93.
doi: 10.1073/pnas.1521740112
221. Berrien-Elliott MM, Sun Y, Neal C, Ireland A, Trissal MC, Sullivan
RP, et al. MicroRNA-142 is critical for the homeostasis and function
of Type 1 innate lymphoid cells. Immunity. (2019) 51:479–90.e6.
doi: 10.1016/j.immuni.2019.06.016
222. Bezman NA, Chakraborty T, Bender T, Lanier LL. miR-150 regulates the
development of NK and iNKT cells. J Exp Med. (2011) 208:2717–31.
doi: 10.1084/jem.20111386
223. Degouve S, Tavares A, Viel S, Walzer T, Marçais A. NKp46-mediated Dicer1
inactivation results in defective NK-cell differentiation and effector functions
in mice. Eur J Immunol. (2016) 46:1902–11. doi: 10.1002/eji.201546163
224. Sullivan RP, Leong JW, Schneider SE, Ireland AR, Berrien-Elliott MM, Singh
A et al. MicroRNA-15/16 antagonizes Myb to control NK cell maturation. J
Immunol. (2015) 195:2806–17. doi: 10.4049/jimmunol.1500949
225. Trotta R, Chen L, Ciarlariello D, Josyula S,Mao C, Costinean S, et al. miR-155
regulates IFN-γ production in natural killer cells. Blood. (2012) 119:3478–85.
doi: 10.1182/blood-2011-12-398099
226. Zawislak CL, Beaulieu AM, Loeb GB, Karo J, Canner D, Bezman NA, et
al. Stage-specific regulation of natural killer cell homeostasis and response
against viral infection by microRNA-155. Proc Natl Acad Sci U S A. (2013)
110:6967–72. doi: 10.1073/pnas.1304410110
227. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA targets.
Cell. (2005) 120:15–20. doi: 10.1016/j.cell.2004.12.035
228. Silver JS, Humbles AA. NK cells join the plasticity party. Nat Immunol.
(2017) 18:959–60. doi: 10.1038/ni.3817
229. Cella M, Otero K, Colonna M. Expansion of human NK-22 cells with IL-7,
IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc Natl Acad Sci
USA. (2010) 107:10961–6. doi: 10.1073/pnas.1005641107
230. Bernink JH, Krabbendam L, Germar K, De Jong E, Gronke K, Kofoed-
Nielsen M, et al. Interleukin-12 and−23 control plasticity of CD127(+)
group 1 and group 3 innate lymphoid cells in the intestinal lamina propria.
Immunity. (2015) 43:146–60. doi: 10.1016/j.immuni.2015.06.019
231. Cella M, Gamini R, Secca C, Collins PL, Zhao S, Peng V, et al.
Subsets of ILC3-ILC1-like cells generate a diversity spectrum of innate
lymphoid cells in human mucosal tissues. Nat Immunol. (2019) 20:980–91.
doi: 10.1038/s41590-019-0425-y
232. Geremia A, Arancibia-Carcamo CV, Fleming MP, Rust N, Singh
B, Mortensen NJ, et al. IL-23-responsive innate lymphoid cells are
increased in inflammatory bowel disease. J Exp Med. (2011) 208:1127–33.
doi: 10.1084/jem.20101712
233. Song C, Lee JS, Gilfillan S, Robinette ML, Newberry RD, Stappenbeck
TS, et al. Unique and redundant functions of NKp46+ ILC3s in
models of intestinal inflammation. J Exp Med. (2015) 212:1869–82.
doi: 10.1084/jem.20151403
234. Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, et al.
Communicable ulcerative colitis induced by T-bet deficiency in the innate
immune system. Cell. (2007) 131:33–45. doi: 10.1016/j.cell.2007.08.017
235. Powell N, Walker AW, Stolarczyk E, Canavan JB, Gokmen MR, Marks
E, et al. The Transcription Factor T-bet Regulates Intestinal Inflammation
Mediated by Interleukin-7 Receptor(+) innate lymphoid cells. Immunity.
(2012) 37:674–84. doi: 10.1016/j.immuni.2012.09.008
236. Viant C, Rankin LC, Girard-Madoux MJ, Seillet C, Shi W, Smyth MJ,
et al. Transforming growth factor-beta and Notch ligands act as opposing
environmental cues in regulating the plasticity of type 3 innate lymphoid
cells. Sci Signal. (2016) 9:ra46. doi: 10.1126/scisignal.aaf2176
237. Bal SM, Bernink JH, NagasawaM, Groot J, Shikhagaie MM, Golebski K, et al.
IL-1beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in
human airway inflammation in the lungs. Nat Immunol. (2016) 17:636–45.
doi: 10.1038/ni.3444
238. Lim AI, Menegatti S, Bustamante J, Le Bourhis L, Allez M, Rogge L, et al.
IL-12 drives functional plasticity of human group 2 innate lymphoid cells. J
Exp Med. (2016) 213:569–83. doi: 10.1084/jem.20151750
239. Ohne Y, Silver JS, Thompson-Snipes L, Collet MA, Blanck JP, Cantarel
BL, et al. IL-1 is a critical regulator of group 2 innate lymphoid cell
function and plasticity. Nat Immunol. (2016) 17:646–55. doi: 10.1038/ni.
3447
240. Silver JS, Kearley J, Copenhaver AM, Sanden C, Mori M, Yu L, et al.
Inflammatory triggers associated with exacerbations of COPD orchestrate
plasticity of group 2 innate lymphoid cells in the lungs. Nat Immunol. (2016)
17:626–35. doi: 10.1038/ni.3443
241. Garrido-Mesa N, Schroeder JH, Stolarczyk E, Gallagher AL, Lo JW, Bailey
C, et al. T-bet controls intestinal mucosa immune responses via repression
Frontiers in Immunology | www.frontiersin.org 22 July 2020 | Volume 11 | Article 813
Stokic-Trtica et al. NK and ILC Development
of type 2 innate lymphoid cell function.Mucosal Immunol. (2019) 12:51–63.
doi: 10.1038/s41385-018-0092-6
242. Cortez VS, Fuchs A, Cella M, Gilfillan S, Colonna M. Cutting edge: salivary
gland NK cells develop independently of Nfil3 in steady-state. J Immunol.
(2014) 192:4487–91. doi: 10.4049/jimmunol.1303469
243. Cording S, Medvedovic J, Lecuyer E, Aychek T, Dejardin F, Eberl G. Mouse
models for the study of fate and function of innate lymphoid cells. Eur J
Immunol. (2018) 48:1271–80. doi: 10.1002/eji.201747388
244. Merzoug LB, Marie S, Satoh-Takayama N, Lesjean S, Albanesi M, Luche H,
et al. Conditional ablation of NKp46+ cells using a novel Ncr1(greenCre)
mouse strain: NK cells are essential for protection against pulmonary B16
metastases. Eur J Immunol. (2014) 44:3380–91. doi: 10.1002/eji.201444643
245. Rankin LC, Girard-Madoux MJ, Seillet C, Mielke LA, Kerdiles Y, Fenis A,
et al. Complementarity and redundancy of IL-22-producing innate lymphoid
cells. Nat Immunol. (2016) 17:179–86. doi: 10.1038/ni.3332
246. Liao N, Bix M, Zijlstra M, Jaenisch R, Raulet D. MHC class I deficiency:
susceptibility to natural killer (NK) cells and impaired NK activity. Science.
(1991) 253:199–202. doi: 10.1126/science.1853205
247. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human
NK cell education by inhibitory receptors for MHC class I. Immunity. (2006)
25:331–42. doi: 10.1016/j.immuni.2006.06.013
248. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell. (2010)
142:847–56. doi: 10.1016/j.cell.2010.08.031
249. Johansson S, Johansson M, Rosmaraki E, Vahlne G, Mehr R, Salmon-Divon
M, et al. Natural killer cell education in mice with single or multiple major
histocompatibility complex class I molecules. J Exp Med. (2005) 201:1145–
55. doi: 10.1084/jem.20050167
250. Held W, Raulet DH. Ly49A transgenic mice provide evidence for a
major histocompatibility complex-dependent education process in NK cell
development. J Exp Med. (1997) 185:2079–88. doi: 10.1084/jem.185.12.2079
251. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L,
et al. Licensing of natural killer cells by host major histocompatibility
complex class I molecules. Nature. (2005) 436:709–13. doi: 10.1038/nature
03847
252. He Y, Tian Z. NK cell education via nonclassical MHC and non-MHC
ligands. Cell Mol Immunol. (2017) 14:321–30. doi: 10.1038/cmi.2016.26
253. Lowin-Kropf B, Kunz B, Beermann F, Held W. Impaired natural
killing of MHC class I-deficient targets by NK cells expressing a
catalytically inactive form of SHP-1. J Immunol. (2000) 165:1314–21.
doi: 10.4049/jimmunol.165.3.1314
254. Wahle JA, Paraiso KH, Kendig RD, Lawrence HR, Chen L, Wu J,
et al. Inappropriate recruitment and activity by the Src homology region
2 domain-containing phosphatase 1 (SHP1) is responsible for receptor
dominance in the SHIP-deficient NK cell. J Immunol. (2007) 179:8009–15.
doi: 10.4049/jimmunol.179.12.8009
255. Viant C, Fenis A, Chicanne G, Payrastre B, Ugolini S, Vivier E.
SHP-1-mediated inhibitory signals promote responsiveness and anti-
tumour functions of natural killer cells. Nat Commun. (2014) 5:5108.
doi: 10.1038/ncomms6108
256. Guia S, Jaeger BN, Piatek S, Mailfert S, Trombik T, Fenis A, et al.
Confinement of activating receptors at the plasma membrane
controls natural killer cell tolerance. Sci Signal. (2011) 4:ra21.
doi: 10.1126/scisignal.2001608
257. Zafirova B, Mandaric S, Antulov R, Krmpotic A, Jonsson H, Yokoyama
WM, et al. Altered NK cell development and enhanced NK cell-mediated
resistance to mouse cytomegalovirus in NKG2D-deficient mice. Immunity.
(2009) 31:270–82. doi: 10.1016/j.immuni.2009.06.017
258. Jelencic V, Sestan M, Kavazovic I, Lenartic M, Marinovic S, Holmes TD,
et al. NK cell receptor NKG2D sets activation threshold for the NCR1
receptor early in NK cell development. Nat Immunol. (2018) 19:1083–92.
doi: 10.1038/s41590-018-0209-9
259. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N,
et al. NKG2D-deficient mice are defective in tumor surveillance
in models of spontaneous malignancy. Immunity. (2008) 28:571–80.
doi: 10.1016/j.immuni.2008.02.016
260. Elliott JM, Wahle JA, Yokoyama WM. MHC class I-deficient natural
killer cells acquire a licensed phenotype after transfer into an
MHC class I-sufficient environment. J Exp Med. (2010) 207:2073–9.
doi: 10.1084/jem.20100986
261. Ebihara T, Jonsson AH, Yokoyama WM. Natural killer cell licensing in mice
with inducible expression of MHC class I. Proc Natl Acad Sci USA. (2013)
110:E4232–7. doi: 10.1073/pnas.1318255110
262. Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier
E, et al. Altered NKG2D function in NK cells induced by chronic
exposure to NKG2D ligand-expressing tumor cells. Blood. (2005) 106:1711–
7. doi: 10.1182/blood-2005-03-0918
263. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, et al.
Sustained localized expression of ligand for the activating NKG2D receptor
impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.
Nat Immunol. (2005) 6:928–37. doi: 10.1038/ni1239
264. Tripathy SK, Keyel PA, Yang L, Pingel JT, Cheng TP, Schneeberger A,
et al. Continuous engagement of a self-specific activation receptor induces
NK cell tolerance. J Exp Med. (2008) 205:1829–41. doi: 10.1084/jem.200
72446
265. Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M,
Ludwig A, et al. Tumor-associated MICA is shed by ADAM proteases.
Cancer Res. (2008) 68:6368–76. doi: 10.1158/0008-5472.CAN-07-6768
266. Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, et al. Antitumor
immunity. A shed NKG2D ligand that promotes natural killer cell activation
and tumor rejection. Science. (2015) 348:136–9. doi: 10.1126/science.12
58867
267. Sanchez-Correa B, Lopez-Sejas N, Duran E, Labella F, Alonso C, Solana R,
et al. Modulation of NK cells with checkpoint inhibitors in the context of
cancer immunotherapy. Cancer Immunol Immunother. (2019) 68:861–70.
doi: 10.1007/s00262-019-02336-6
268. Schumacher TN, Scheper W, Kvistborg P. Cancer neoantigens.
Annu Rev Immunol. (2019) 37:173–200. doi: 10.1146/annurev-
immunol-042617-053402
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Stokic-Trtica, Diefenbach and Klose. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 23 July 2020 | Volume 11 | Article 813
